

**MAY 2025**

# ESTABLISHING OF CANCER MISSION HUBS: NETWORKS AND SYNERGIES

**Project Book**




Funded by  
the European Union



# ECHoS

Cancer Mission Hubs



**Funded by  
the European Union**

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

# CONTENTS

## 02 FOREWORDS

## 07 OVERVIEW

08. Introduction

09. Objectives

11. Structure

## 12 WORK PACKAGES

13. WP1 | Project Governance and Implementation

14. WP2 | National Cancer Mission HUBs design, creation and Knowledge Exchange

15. WP3 | Multi-stakeholder identification, engagement and cooperation

16. WP4 | Synergies: bridges to Missions and other European initiatives

17. WP5 | Future EU network of National Cancer Mission HUBs – Design Study

18. WP6 | Communication, Dissemination, Citizens' Engagement & Participation

## 19 ECHoS CONSORTIUM

20. ECHoS Together

21. ECHoS Executive Board

23. ECHoS Scientific Advisory Board

27. Get to know the ECHoS Consortium

91. Acknowledgments

# FOREWORDS





## Anabela Isidro & Hugo Soares

ECHoS Coordinators

---

As Coordinators of ECHoS it is a great honour to lead a consortium that includes such a prestigious group of organisations, 57(!) from 25 Member States, 3 Associated Countries, and a transnational European Organisation, with the common goal of supporting the implementation of EU Mission on Cancer.

By establishing National Cancer Mission Hubs (NCMHs) in each MS/AC, European citizens and organizations in health, research and beyond will be voiced and their voices will echo together. In the next three years, we, together with partners all over Europe, will advocate for the implementation of the objectives of the Cancer Mission at National, Regional, and Local levels - altogether contributing to improving the lives of 3 million people by 2030.

It is therefore with the highest sense of responsibility that we commit ourselves to create the foundations on NCMHs in each MS/AC and capacitate each one, through knowledge sharing and networking, to create real life impact in cancer care and research. Breaking Through Cancer.



*I welcome this important initiative of the Cancer Mission. The future National Cancer Mission Hubs will enhance Member States' capacities to integrate EU cancer research and policy actions at national, regional, and local levels. By supporting cross-policy dialogues with stakeholders, these hubs will create a seamless link between R&I and policy developments. This is great news for EU citizens, who will be the key focus of the Mission Hubs' activities.*

Mariya Gabriel

European Commissioner for Innovation, Research, Culture, Education and Youth



*ECHoS will facilitate and accelerate integration of Cancer Mission activities at the national and regional level. It will provide them with the capacity to gradually create permanent structures dedicated to the integration of the Cancer Mission, providing guidelines and best practices for efficient stakeholder mobilisation and participation taking into consideration the differences in national health and research systems. The future network of mission hubs will serve as a platform for national and regional actors across the EU, for best practices exchanges and joint activities.*

Joanna Drake  
Deputy Director-General for Research and Innovation





## Ioannis Vouldis

European Health and Digital Executive  
Agency (HaDEA) - EC

---

EU Missions are a novelty of the Horizon Europe research and innovation programme, aiming to address some of the greatest challenges in our society. The goal of the Mission on Cancer is to improve the lives of more than 3 million people by 2030, through prevention, cure and support a better and longer life for those affected by cancer including their families.

In this context, the ECHoS project 'Establishing of Cancer Mission Hubs: Networks and Synergies' is granted 6 million euros funding to support the implementation of the Cancer Mission activities in the EU Member States and Associated Countries through the establishment and development of Cancer Mission Hubs operating at national, regional and local levels.

As the responsible EU Officer for ECHoS, I feel privileged working together with the ECHoS coordination team, their partners and stakeholders, to help meeting the project objectives and yield fruitful results. And in doing so, contributing to the Cancer Mission being delivered, thus helping people to lead healthier lives in Europe and beyond.





# OVERVIEW



## INTRODUCTION

Cancer is a major and growing societal challenge. The increasing incidence of cancer and the introduction of expensive innovative diagnostics, therapeutics, and care interventions makes it an everyday growing economic burden to European healthcare systems. To face this reality, the European Commission has set ambitious and innovative collaborative efforts, as part of the European Beating Cancer Plan (EBCP) and of Horizon Europe (HE), to integrate cancer control measures based on the outputs of fundamental, translational, and clinical research. Alongside this, the EU has invested in several innovation measures to foster R&I in the private sector, as well as to enable greater citizen participation, together with policy, and legislation support. While the organization of cancer awareness and control initiatives at various levels is laudable, there is a potential concern that a disconnected approach may dilute efforts and bring confusion to citizens, in addition to researchers and healthcare professionals.


Through Cancer Mission, EC appeals Member States and Associated Countries (MS/AC) to **combine research, innovation, and policy development**, in ways that cannot be achieved through individual and fragmented initiatives. The ambition of **ECHoS** is to further support the Cancer Mission by providing MS/AC with the capacity to gradually create **National Cancer Mission Hubs (NCMHs)** operating at national, regional and, where relevant, local levels. These NCMHs will have a **key role in involving all relevant national, regional, and local stakeholders, including citizens, in cancer-related policy dialogues**.

Aligned with the ambition of EU Mission Cancer, the driving force of ECHoS project is **"To improve the lives of more than 3 million people by 2030 through prevention, cure and for those affected by cancer including their families, to live longer and better"**.

IN 2020<sup>1</sup> ...



...2.7 million people in the EU-27 were diagnosed with cancer...



... and 1.3 million die from the disease.

1. ECIS - European Cancer Information System, available at <https://ecis.jrc.ec.europa.eu/>

## OBJECTIVES

The primary aim of ECHoS is to support the implementation of the Cancer Mission activities in all Member States and Associated Countries through the establishment and **development of Cancer Mission Hubs** operating at national, regional and local levels. ECHoS will set the foundations for the creation of a future European Network of National Cancer Mission Hubs (EU network of NCMHs) with the ambition to be **a strong and cohesive network**, aligned with the Cancer Mission and EBCP, that will continue fostering collaborative research, as well as citizen and other stakeholder engagement efforts. ECHoS will engage with stakeholders across the entire cancer landscape, from individual citizens to European Institutions, as well as national authorities, regulators, industry, patient organizations, and academia. ECHoS broad scope aims to **take cancer-policy dialogues beyond research and innovation and health systems covering also other relevant areas in cancer control and support such as employment, education, and socio-economic aspects**. To guarantee alignment and progress in the field of cancer, ECHoS will be guided by impacting subareas of Cancer Mission – namely **prevention, early detection and treatment, quality of Life and survivorship** – as well as equity, sustainability, and cross-cutting EU priorities such as social engagement and digital health.

Our aim is to **support the implementation of the Cancer Mission activities in all MS/AC...**

**...through the establishment and development of National Cancer Mission Hubs.**


**To promote the creation of National Cancer Mission Hubs in MS/AC**

**To establish a network of support to advance Cancer Mission across Europe**

**To create synergies for the implementation of the Cancer Mission** with other European initiatives towards a "Cancer in All" approach

**To create the foundations for a European network of NCMHs** by developing a business continuity and operations model framework.

## NETWORKS & SYNERGIES



## STRUCTURE

All partners have **key roles** in their respective countries: in cancer care, research, as well as research and health policies. These partners include **citizens, industry, SMEs, academia, governance, hospitals and infrastructures**. Many are involved in community engagement activities and/or defining cancer-control strategies. Together, they form a **strong pool of knowledge and expertise** to reach General and Specific project objectives.



**WP1**  
Project Governance and Implementation



**WP2**  
National Cancer Mission Hubs:  
Design, Creation and Knowledge Exchange



**WP3**  
Multi-stakeholder Identification,  
Engagement, and Cooperation



**WP4**  
Synergies: bridges to Missions and  
other European initiatives



**WP5**  
Future EU network of Cancer  
Mission Hubs - Design Study




**WP6**  
Communication, Dissemination,  
Citizens' Engagement &  
Participation



# WORK PACKAGES

A decorative graphic consisting of a horizontal row of overlapping circles, rendered in a light gray color, positioned directly beneath the 'WORK PACKAGES' text.

## WP1 | Project Governance and Implementation



Led by AICIB, WP1 will be dedicated to all the **management procedures for the day-to-day operations of the project**. These include the coordination of project activities, support to WPs, preparing for project meetings, and delivery of periodic reports to the EC. This WP will also monitor the implementation NCMHs across participating MS/AC and their activities as a measure of impact of the project.

### TASKS:

**Task 1.1** | Project Coordination and Project Management (AICIB, PT)

**Task 1.2** | Project Governance and support to Governance structure (AICIB, PT)

**Task 1.3** | Monitoring and Evaluation of Project Implementation (Tecnalia, ES)

### THE OBJECTIVE OF WP1 IS TO ENSURE AN EFFICIENT COORDINATION AND MANAGEMENT OF THE ECHOS PROJECT BY:

- **Operational level**, manage the progress of project activities according to the timely fulfilment of the milestones and deliverables within the planned resources.
- **Strategic level**, make necessary adjustments to technological, scientific, economical, or legal aspects, if needed, to guarantee the course set out in the description of work.
- **Institutional level**, manage the consortium's relationship with the European Commission by ensuring that all the required documentation will be delivered according to the applicable rules and procedures.
- **Consortium level**, ensure a regular and up-to-date flow of relevant information among all partners.
- **Outcome level assess**, the impact and performance through monitoring of project results.
- **Ethical and legal level**, to ensure that all relevant ethical standards and guidelines.

## WP2 | National Cancer Mission HUBs design, creation and Knowledge Exchange



Led by INT, WP2 will be dedicated to the **definition of the basis, general design and the operative NCMH structural elements**. These are envisaged as new conceptual initiatives that aim to break silos in health care, research, and innovation: creating bridges within and beyond this triangle in the cancer area. Guidelines, best practices, capacity building in knowledge exchange programs and awareness events will serve to promote NCMHs establishment.

### TASKS:

**Task 2.1** | Definition of general design and operative NCMH structural elements (INT, IT)

**Task 2.2** | Guidelines and best practices for the implementation of NCMHs (NIO-PIB, PL)


**Task 2.3** | Capacity Building: Knowledge exchange program (Sciensano, BE, and InoMed, RO)

**Task 2.4** | Support the development of NCMHs awareness events in MS/AC (AICIB, PT)

### THE OBJECTIVE OF WP2 IS TO DEFINE THE GROUNDS AND PROMOTE NATIONAL CANCER MISSION HUBS ESTABLISHMENT BY:

- **Generating concept models of NCMHs**, aligned with the Cancer Mission Implementation Plan, including the definition of minimal criteria for inclusion.
- **Mapping and categorization** of structures hubs, agencies, mirror groups, informal groups, initiatives operating in MS/AC participating in ECHoS.
- **Creating a manual with guidelines**, best practice, real-world inspirational examples, and a set of recommendations for the creation of NCMHs.
- **Developing an internal knowledge sharing program** stimulating sharing of best practices and mutual learning among organizations.
- **Supporting the development of meetings and events** to raise awareness for NCMHs in MS/AC.





## WP3 | Multi-stakeholder identification, engagement and cooperation

Coordinated by Center for Innovation in Medicine (InoMed, Romania), WP3 will be dedicated to **helping NCMHs identify, engage, connect, and enable traditional and non-traditional organized stakeholders** to actively and impactfully contribute to the success of the Cancer Mission.

### TASKS:

**Task 3.1** | Establish impact models to support implementation of Mission on Cancer (SIR, SE)


**Task 3.2** | Identify stakeholders and create an interactive tool for stakeholder interactions at MS/AC, Regional and local level (HUS, FI)

**Task 3.3** | Engage individual stakeholders and foster cooperation (OCC, NO)

### THE OBJECTIVE OF WP3 IS TO ESTABLISH CONNECTIONS AND ENGAGE STAKEHOLDERS TO CONTRIBUTE TO THE SUCCESS OF CANCER MISSION:

- **Develop suitable impact models** for the Cancer Mission subareas that will contribute to the overall success of the Cancer Mission, by providing NCMHs with a blueprint to adapt to national context and priorities, allow them to rapidly engage relevant stakeholders and identify critical activities and necessary milestones.
- Based on impact models, **systematically engage relevant stakeholder groups**, and stimulate bottom-up cancer-mission activities,
- **Foster multi-stakeholder co-operation** by building a shared culture around Cancer Mission.
- **Establish an interactive tool** to map stakeholders across all groups in a way that enables new connections, and to encourage Mission activities among different stakeholders.

## WP4 | Synergies: bridges to Missions and other European initiatives



Led by Xjenza Malta (XM, Malta), WP4 will be dedicated to **investing in the generation of collaborations with European Projects and organizations in Health, Research and Beyond**. WP4 will initiate and strengthen synergies between ECHoS (and NCMHs) with other European bodies, initiatives and actors to ensure that there is an effective policy dialogue at all levels and to allow an effective connection with such initiatives.

### TASKS:

**Task 4.1** | Creation of a Liaison Committee for high-level representation and Policy dialogues (AICIB, PT)

**Task 4.2** | Operational level synergies with EU initiatives (EKT, GR & UCSC, IT)

**Task 4.3** | 'Cancer in all policies'- synergies beyond Health (XM, MT)

### THE OBJECTIVE OF WP4 IS TO INITIATE AND STRENGTHEN SYNERGIES BETWEEN ECHOS (AND NCMHS) WITH OTHER EUROPEAN BODIES, INITIATIVES AND ACTORS:

- **Ensure broad (European, national, regional, local) involvement** of actors in the cancer policy dialogue, particularly with EU Institutions, National Authorities, Cancer Mission amongst others.
- **Ensure broad stakeholders' involvement**, including patients and citizens, in policy dialogue on cancer.
- **Identify potential synergies with other areas** to contribute to the success of the Mission.

## WP5 | Future EU network of National Cancer Mission HUBs – Design Study



Coordinated by Sciensano (Belgium), WP5 will be dedicated to developing a sustainable business continuity model to the future network of NCMHs. WP5 will **build on the outcomes and outputs of WP2 and its potential adaptations to different national contexts**. Adjustments are envisioned according to the needs identified in WP3, WP4, and WP6 in respect to interaction with organized stakeholders, synergies with other European initiatives, and individual citizens, respectively.

### TASKS:

**Task 5.1** | Define scope of the EU network of National Cancer Mission Hubs (Sciensano, BE)

**Task 5.2** | Business-continuity framework – governance, finance and business models (NIO-PIB, PL)

**Task 5.3** | Strategic roadmap for a sustainable European Network of Cancer Mission Hubs (AICIB, PT)

### THE OBJECTIVE OF WP5 IS TO BUILD AN OPERATIONAL BLUEPRINT OF THE FUTURE EU STRUCTURE THAT WILL CONNECT NCMHS TRANSNATIONALLY:

- **Identification of potential sustainability models**, including both ‘classic’ and innovative approaches to fund-raising activities, business models, and legal status of the future network of NCMHs.
- **Development of a Network “Business-continuity model” framework** taking into consideration NCMHs diversity and governance, and a particular focus on citizen participation and policy dialogue activities.
- **Develop a roadmap** for the sustainable implementation of an EU network of NCMHs.

## WP6 | Communication, Dissemination, Citizens' Engagement & Participation



Led by Karolinska Comprehensive Cancer Centre (KCCC) - joint initiative between the Karolinska University Hospital (KHU, Sweden) and the Karolinska Institute (KI, Sweden) - WP6 will be dedicated to **bringing the Cancer Mission to those who need it the most: citizens**. WP6 will focus on Communication activities across all required levels and, also, targeting non-organized stakeholders - namely citizens, patients and their families, marginalized groups, and the society at large.

### TASKS:

**Task 6.1** | Dissemination and Communication (AICIB, PT)

**Task 6.2** | Citizens' Engagement and Participation Activities (GOEG, AT)

**Task 6.3** | Organization of Transnational citizens' engagement events (SIR & KCCC, SE)

### THE OBJECTIVE OF WP6 IS TO ESTABLISH COMMUNICATION CHANNELS THAT SUPPORT AND ENHANCE THE MISSION APPROACH :

- **Communication:** Communicate across all required levels to support top-down / bottom-up mission approach.
- **Citizen engagement and participation:** Ensure broad citizen engagement and participation.
- **Dissemination and Awareness Events:** Facilitate 'added European dimension' to national events and effectively disseminate information about local cancer-related events as well as organize cross-cutting events.
- **Impact:** Ensure the long-term impact of the action by establishing a 'roadmap to impact', including but not limited to a self-sustaining hubs ecosystem, tools, and trainings to support NCMHs on the way to get there and the exploitation of results and resources obtained during the project.

# ECHoS CONSORTIUM

The logo graphic for ECHoS Consortium consists of a series of white, stylized, overlapping semi-circular shapes arranged in a horizontal row, resembling a series of connected arches or a stylized wave.


## ECHoS TOGETHER

Committed to achieving its goals, ECHoS consortium gathers **58 organizations** distributed across **28 countries** covering the entire cancer ecosystem. Partner organizations in the consortium include **Public Health Organisations, Ministries of Science, Ministries of Health, National Funding Agencies, Innovation Centres, Universities, Cancer Centres. Associations, and other organizations from both the public and private sectors.**

Some countries already have operational Cancer Hub-like structures that can contribute to ECHoS with valuable experiences and share prior knowledge sharing in multiple areas. These structures include the Portuguese National Cancer Hub, the Belgium EBCCP Mirror Group, the Swedish Vision Zero Cancer initiative, the Strategy Committee of the German National Decade Against Cancer, the Romanian Cancer Mission Informal Group, and the Spanish Core Mirror Group for Cancer Mission just to name a few.

ECHoS will leverage on these national structures and liaise with the established network of National Contact Points for HE and National Focal Points for EU4Health and other appointed delegates to multiple European initiatives towards the creation of competences and know-how to facilitate the creation of competent NCHMs in all MS/AC. In addition, ECHoS will establish key synergies with the CSAs 4.UNCAN.EU, CCI4EU, the Joint Actions JaNe and CraNe, and other key European initiatives (e.g. EUCAIM project), to guarantee Mission on Cancer objectives are implemented in multiple sectors. **Identified synergies, and others that will emerge during the project, will promote an alignment of programmes and strategies decreasing duplication of efforts aiming to defragment and increase the impact of cancer research and health initiatives.** It will also create communication channels between EU initiatives and individual NCMHs, leading to a wider implementation of Cancer Mission-related activities.

**Participating countries:** Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and Turkey.



## ECHoS EXECUTIVE BOARD

All partners are vested with interest on the successful implementation of Cancer Mission activities in their respective country or region and are experienced professionals in cancer care, cancer research, research- and health-policies and many are involved in health community engagement (e.g., citizens, industry, SMEs, academia, governance, hospitals...). The Executive Board Team is composed of representatives of organizations with leadership roles in the project, both at WP or Task level.



**Anabela Isidro**

AICIB, PT



**Hugo Soares**

AICIB, PT



**Giovanni**

**Apolone**

INT, IT



**Marius Geanta**

InoMed, RO



**Ian Gauci Borda**

Xjenza Malta, MT



**Marc Van Den**

**Bulcke**

SCIENSANO, BE



**Ebba Hallersjö**

**Hult**

SIR, SE



**Claudia Habi**

GOEG, AT



**Olatz Murua**

TECNALIA, ES



**Iwona Lugowska**

NIO-PIB, PL

## ECHoS EXECUTIVE BOARD (cont.)



**Dorota Dudek-  
Godeau**  
NIO-PIB, PL



**Tomi Makela**  
FICAN, FI



**Ketil Widerberg**  
OCC, NO



**Marine  
Jeanmougin**  
OCC, NO



**Stefania Boccia**  
UCSC, IT



**Tommaso Osti**  
UCSC, IT



**Sofia Xesfingi**  
EKT, GR




**Angelos  
Angelidis**  
EKT, GR



**Eva Jolly**  
KUH and KCCC, SE



**Abdelrahman  
Taha**  
UCSC, IT



**Mirjami Tran  
Minh**  
FICAN, FI



## ECHoS STRATEGIC ADVISORY BOARD

The ECHoS Strategic Advisory Board is composed of an external group of multidisciplinary and diverse key opinion leaders to advise on project governance and activities and act in the best interest of the project bridging ECHoS with relevant players in the Cancer area.

### Aim

Provide advice on the project objectives and results to ensure that the activities are sound, pertinent and provide high impact to the community.

Providing **valuable insights** on:



- **Strategic direction** of the project
- **Key operational**, technical matters
- **Exploitation and impact** of the projects results



### Barbara Radecka

Department of Oncology, Institute of Medical Sciences, University of Opole, Poland; Department of Clinical Oncology, Tadeusz Koszarowski Cancer Center in Opole



### Ivana Cattaneo

Executive Director, Therapeutic Area Advocacy and Precision Medicine at Novartis



### Jan Geissler

Past chair of WECAN, Founder and CEO of Patvocates



### Sarah Stroobants

NCP Advisor for Health & Missions at NCP Flanders / Research Foundation Flanders



### Jose M Martin-Moreno

Professor of Preventive Medicine and Public Health at the University of Valencia, Spain and Policy Adviser, European Observatory on Health Systems and Policies



## Barbara Radecka

Department of Oncology, Institute of Medical Sciences, University of Opole, Poland;  
Department of Clinical Oncology, Tadeusz Koszarowski Cancer Center in Opole

Barbara Radecka is a Clinical Oncologist and assistant professor, Head of the Department of Oncology at the Institute of Medical Sciences, University of Opole (Uniwersytet Opolski) and Tadeusz Koszarowski Cancer Center (Opolskie Centrum Onkologii w Opolu) in Opole. Her main scientific interests are Breast Cancer and Colorectal Cancer.

The topic of her doctoral dissertation is “Long-term results of breast cancer recurrence treatment in patients after primary surgical treatment”, and her habilitation thesis is “Pathomorphological complete response after preoperative chemotherapy in breast cancer patients”.

She is a member of Polish and international research teams and co-author of several papers published in indexed journals. Scholarship holder of the ESMO - European Society for Medical Oncology at the Institut Jules Bordet in Brussels in 2009. She is a member of the Polish Society of Clinical Oncology (Vice-president of the main board) and Polish Oncological Society (member of the peer jury).



## Ivana Cattaneo

Executive Director, Therapeutic Area Advocacy and Precision Medicine at Novartis

Ivana is the Executive Director of Therapeutic Area Advocacy and Precision Medicine at Novartis. She has an MSc in International Health Technology Assessment from The University of Sheffield, Faculty of Medicine, Dentistry and Health, a master's in management and a degree in foreign literature from Italian Universities.

She is passionate about Cancer Policy and focuses on policy advocacy on Cancer Research, Cancer challenges, access, and inequalities. Her work experience is at the international level, primarily in life science industry.

Ivana is a member of different steering committees such as:

- Chair of the EFPIA - European Federation of Pharmaceutical Industries and Associations Oncology Platform
- Steering Committee member of ESMO - European Society for Medical Oncology Rare Cancers Europe
- Founding member of Transforming Breast Cancer Together
- Member of the Cancer Grand Challenges Advocacy Panel
- Member of the PROPHET.EU Stakeholder Forum



## Jan Geissler

Past chair of WECAN, Founder and  
CEO of Patvocates

As a patient living with Chronic Myeloid Leukemia, Jan Geissler co-founded the patient advocacy organisations LeukaNET, CML Advocates Network, Acute Leukemia Advocates Network and the network of pan-European cancer patient organisations (WECAN). He is the founder and CEO of Patvocates, a think tank and social venture on patient involvement and patient advocacy, and founder and managing director of the non-profit European Patient Advocacy Institute (EPAI).

Jan serves as an advisor e.g., on the Patient Advisory Committees of the European Cancer Organisation and the European Hematology Association. He is on the strategy council of the German National Decade Against Cancer and the steering committee of the German National Cancer Plan. Jan is involved in the EU projects HARMONY Alliance and SafePolyMed. He also serves as lay member on the Bavarian Chamber of Physicians Ethics Committee.



## Jose M Martin-Moreno

Professor of Preventive Medicine and Public  
Health at the University of Valencia, Spain  
and Policy Adviser, European Observatory  
on Health Systems and Policies

Jose M Martin-Moreno is a Professor of Medicine and Public Health at the University of Valencia, Director of the Medical Education and Quality Unit at the Valencian Clinical Hospital, Director of the Andrija Stampar European Summer School of Public Health and Policy Adviser of the European Observatory on Health Systems and Policies.

Dr. Martin-Moreno is also a Member of the European Academy of Cancer Sciences, Core Faculty Member of the European School of Oncology and of the European Code Against Cancer Scientific Committee, and Member of the ESMO European Policy and Global Policy Committees.

He previously served as Director of Programme Management at WHO Europe and Director-General and Chief Medical Officer of Spain. Additionally, he has also advised the European Commission (through diverse working groups organized under the Directorate General for Health and Consumers, DG SANCO, and the Directorate General of Research, DG Research), the Scientific and Technical Office of the European Parliament, the European Institute of Oncology, and the International Agency for Research on Cancer.



## Sarah Stroobants

NCP Advisor for Health & Missions at NCP  
Flanders / Research Foundation Flanders

Sarah Stroobants is a National Contact Point Advisor for the Health domain, including the Cancer Mission, at Research Foundation Flanders. In that role, she provides information and advice to potential applicants and beneficiaries of the Horizon Europe programme.

Before joining NCP Flanders, Sarah worked at the European Commission's Department for Education and Culture (DG EAC). At the Commission she was responsible for coordinating the relations between DG EAC and the Council of the EU. She provided policy advice and support to her department on inter-institutional processes, including in the context of the legislative negotiations of the EU programmes managed by DG EAC. Before her time at the Commission, Sarah worked at the University of Leuven's international office as an advisor internationalisation.

## PORTUGAL



# Agência de Investigação Clínica e Inovação Biomédica (AICIB)

Agency for Clinical Research and Biomedical Innovation



AICIB (<http://www.aicib.pt>) mission is to promote, coordinate, and support activities in the areas of clinical and translational research and biomedical innovation, contributing to the optimisation of Portugal's clinical, scientific, and technological potential. AICIB activities are structured around 3 strategic pillars: i) Foster clinical research and biomedical innovation; ii) Train and create a national clinical research and biomedical innovation network, and; iii) Stimulate the internationalisation of clinical research and biomedical innovation.

## CONTRIBUTION



AICIB is the coordinator of ECHoS project. It is our responsibility to ensure that all tasks – including performance reporting – are performed on time, on budget and on scope. At the strategic level, it is our responsibility to ensure that ECHoS work is aligned with the aims of EU Mission on Cancer and with the needs of the European community in health, research and beyond by engaging in multiple interactions and policy dialogues at both organisation and citizen's level. In addition, AICIB leads multiple tasks in different work packages, including communication, and is responsible to harmonise and linking needs and competencies of complementary consortium members.

## EXPECTATIONS



The expectations for ECHoS at both European and National levels are quite high. As coordinators our expectation is to be able to support the creation of, at least, 20 new National Cancer Mission Hubs in the next 3 years. But we want more, we want to create a community of researchers, healthcare professionals, and other stakeholders in cancer that interact independently for the creation of innovative solutions – being research projects, new products or services, or the share of experiences and best practice to take maximum benefit from installed competencies.

We expect ECHoS to promote a wider participation of patients and citizens in the entire research continuum (from drafting the idea, to executing, to monitoring and evaluating, and finally to exploitation). We expect that, by the end of ECHoS, more funding agencies, regulatory agencies and other policymakers recognize the importance of engaging multi-stakeholders (citizens and organisations) in both creation and implementation processes. Moreover, we expect this engagement to be aligned with needs and desired impact so that the entire process becomes more efficient thus, sustainable.

In the end, we expect ECHoS to develop a repository of guidelines and tools that can help other organizations to implement relevant, impact-driven, research and policy dialogues in meaningful areas of health and beyond.

PORTUGAL




# Agência de Investigação Clínica e Inovação Biomédica (AICIB)

Agency for Clinical Research and Biomedical Innovation



**Anabela Isidro**  
ECHoS Coordinator



**Hugo Soares**  
ECHoS Co-coordinator



**Yasmin Fonseca**  
ECHoS Project Manager



**José Salvado**  
ECHoS Communication  
Officer




**Laura Gomes**  
ECHoS Financial Officer



**Ana Domingos**  
European Project Manager



## AUSTRIA



# Gesundheit Österreich GmbH (GÖG) The Austrian National Public Health Institute



As the Austrian National Public Health Institute for Health Promotion, Quality, Planning and Research, Gesundheit Österreich GmbH contributes to improve the health of the Austrian population and evaluates, secures and optimises the Austrian Health and Care System.

## CONTRIBUTION

Contribution to WP2 and WP3 and Task Lead of Task 6.2: Citizens' Engagement and Participation Activities, in Work Package 6.

## EXPECTATIONS

Increased engagement of Citizens, including patients, and national, regional, and local stakeholders in the policy dialogue on cancer. Integration of Mission on Cancer activities with activities at national, regional, and local levels. Increased engagement in policy dialogue on cancer for Actors in national, regional, or local health and research and innovation systems.



**Claudia Habl**

Main contact person/Lead



**Barbara Fröschl**

Senior researcher



**Daniela Rojatz**

Researcher



**Wolfgang Seebacher**

Researcher



**Anita Gottlob**

Researcher

## BELGIUM



### European Cancer Organisation (ECO)



The European Cancer Organisation is the largest multi-professional cancer organisation in Europe. It aims to reduce the burden of cancer, improve outcomes and the quality of care for cancer patients, through multidisciplinary and multi-professionalism. As the not-for-profit federation of member organisations working in cancer at a European level, the European Cancer Organisation convenes oncology professionals and patients to agree policy, advocate for positive change and speak up for the European cancer community. More information is available [here](#).

#### CONTRIBUTION



ECO is an active partner in the ECHoS project and dedicated to support achieving the development of Cancer Mission Hubs across European countries. ECO has participated in WP4 as part of the Policy Liaison Committee and in WP6, contributing to the organisation of transnational events such as the Cancer Mission Fair.

#### EXPECTATIONS



Supporting ECHoS' vision to further connect citizens, stakeholders and decision-makers at national level with EU cancer policy ambitions, including the EU Cancer Mission, and stimulate stronger national implementation.



**Richard Price**  
Policy Director



**Norbert Couespel**  
Policy Research & EU  
Projects Manager




**Giuseppe Filiti**  
Communications Officer



**Juliana de Sá**  
Policy Research Officer



## BELGIUM



**Sciensano**  
**Sciensano**



Sciensano ([www.sciensano.be](http://www.sciensano.be)) is a research institute and the national public health institute of Belgium. It is the scientific reference in the field of public health in Belgium, experienced in supporting health policy and policymaking through innovative research, analyses, monitoring activities and expert advice. Over 850 of staff members are committed to human and animal health every day, with science and health central to our mission. Sciensano's strength and uniqueness lie within the holistic and multidisciplinary approach to health, with a focus on the close and indissoluble interconnection between human and animal health and their environment (the “One health” concept). By combining different research perspectives within this framework, Sciensano contributes in its unique way to everybody's health. For this, Sciensano builds on the more than 100 years of scientific expertise of the former Veterinary and Agrochemical Research Centre (CODA-CERVA) and the ex-Scientific Institute of Public Health (WIV-ISP).

### CONTRIBUTION



Sciensano will be leading WP5 working towards the set-up of a future EU network for National Cancer Mission Hubs (NCMH) and potential sustainability models. An experienced team will lead the work and build on previous experiences in leading EU Projects/initiatives, for example the sustainability and stakeholder engagement, and proof of concept development work packages in CraNE, iPAAC, CanCoN, TEHDAS and InfAct JAs.

Sciensano will also lead Task 2.3, contributing to capacity building through the development of a knowledge exchange program. In this task Sciensano will contribute with sharing its experience in setting up the Belgian EBCP Mirror Groups, providing input for the discussion on existing NCMH-like structures that may be used for future NCMH-models.

### EXPECTATIONS



Expectations from WP5 in ECHoS include defining and developing an EU network for National Cancer Mission Hubs (NCMH) that will connect transnationally. This will include engaging with relevant stakeholders and experts to ensure their priorities and needs are considered in the process.

Furthermore, complementing the development of the EU network, WP5 will develop a business continuity framework and a strategic roadmap for the sustainable functioning of the EU networks.

Moreover, the Belgian EBCP Mirror Groups concept will be used as a potential model for NCMHs. Sciensano will lead the capacity building and knowledge exchange program which will build on its experience with the Mirror Groups, and provide input and recommendations to guidelines and best practices.

Finally, the expectation that during ECHoS Sciensano will support building a

## BELGIUM



**Sciensano**  
Sciensano



### EXPECTATIONS (CONT.)



long-standing collaboration with experts in the field and ensure the sustainability of the work of ECHoS beyond the project lifespan. The experience of Sciensano and participation in other EU projects/initiatives enables the creation of synergies across EU projects which will support also the work in ECHoS.



**Marc Van Den  
Bulcke**  
Head of Cancer Centre



**Marie Delnord**  
Senior Expert



**Linda Abboud**  
Senior Expert



**Jinane Ghattas**  
Junior Researcher



**Souhade  
Tabbakalt**  
Project Manager



**Mathieu Brabant**  
Financial Officer

## BULGARIA



### Съвместна Онкологична Национална Мрежа (COHM) Bulgarian Joint Cancer Network (BJCN)



BJCN is a Bulgarian cancer network fostering collaboration among medical and non-medical societies, traditional and non-traditional Stakeholders by aiming to enhance cancer care through synergy, cooperation, and innovation.

#### CONTRIBUTION



The Bulgarian Joint Cancer Network (BJCN) actively contributes to ECHoS by enhancing cancer care through multidisciplinary collaboration, technological innovation, and policy dialogue. As a key player in advancing oncological care in Bulgaria, BJCN's community involvement in EU initiatives and commitment to research and innovation demonstrates dedication to improving patient outcomes and cancer care delivery.

#### EXPECTATIONS



BJCN aims to deepen its collaboration and synergy by empowering the European Mission on Cancer priorities in demo act to the Bulgarian National Cancer Plan through research, innovation, and policy dialogues to enhance cancer care.



**Ivo Petrov**  
Main Coordinator



**Assia Konsoulova**



**Dimitar Kalem**

## CROATIA



### Klinički Bolnički Centar Sestre milosrdnice (KBC SM) Sestre milosrdnice University Hospital Center



KBC SM was founded in 1846, and it is one of the oldest and largest medical institutions in the Republic of Croatia. It provides expertise in health care, diagnostics, treatment, consulting services, scientific research and education. It has 28 reference centres of the Ministry of Health.

#### CONTRIBUTION

As University hospital centre we plan to contribute to the activities planned on European level of the ECHOS project, work as National Cancer Mission Hub for Croatia.

#### EXPECTATIONS

Contribute to the ECHOS long term goals in establishing National Cancer Mission Hubs, meetings and project activities.



#### Ana Fröbe

Principal Hub coordinator  
for Croatia



#### Željka Rakvin

Secretary



#### Davor Vagić

Director, Legal Signatory  
(LSIGN)



#### Mia Primorac

Financial Signatory (FSIGN)



#### Ines Potočnjak

Legal Entity Appointed  
Representative (LEAR)

## CYPRUS



# Cyprus Cancer Research Institute (CCRI)



Cyprus Cancer Research Institute (CCRI) is an independent organisation comprising a coalition of the leading academic, clinical, and diagnostic partners in cancer research; the University of Cyprus (UCY, academic), the Bank of Cyprus Oncology Centre (BoCOC, clinical), and the Karaiskakio Foundation (KF, diagnostics). It is a true interdisciplinary network creating a local, regional, and international lighthouse for dedicated basic & translational cancer research.

## CONTRIBUTION



By fostering the creation of a National Cancer Mission Hub, CCRI will implement strategies to increase awareness at a national level and engage relevant stakeholders for establishing new connections and promote their participation in major political and policy dialogues.

## EXPECTATIONS



CCRI expects the establishment of transnational collaboration networks for the active engagement of stakeholders and citizens in policy changes.



**Anastasia  
Constantinidou**  
Acting Research Director



**Styliani (Stella)  
Michael**  
Research Support Officer –  
LEAR



**Martha Trichina**  
Administrative Officer

## CZECH REPUBLIC



### Fakultní nemocnice Olomouc (FNOL) Olomouc University Hospital



Olomouc University Hospital is one of the largest in-patient hospitals in the Czech Republic. It belongs to a network of university hospitals directly controlled by the Ministry of Health of the Czech Republic.

Olomouc University Hospital is a superior centre in terms of many fields of contemporary medicine. It is also very active in the areas of science research and the education of future health professionals.

#### CONTRIBUTION



Principal contribution of the site is to provide contact for networking activities in the Czech Republic in the area of cancer epidemiology, diagnostic and therapy guidelines and research.

#### EXPECTATIONS



The networking between cancer centers in the Czech Republic will be enhanced including the creation of national guidelines and research collaboration resulting in publications in national and international journals.



**Bohuslav  
Melichar**  
Leading Researcher



**Beatrice  
Mohelnikova**  
Team Member

## CZECH REPUBLIC



# Fakultní nemocnice u sv. Anny v Brně (FNUSA) Mezinárodní centrum klinického výzkumu (ICRC) St. Anne's University Hospital Brno International Clinical Research Center



The International Clinical Research Center at St. Anne's University Hospital is a scientific research institution. We focus on preclinical and clinical research, particularly in the areas of cardiology, neurology and oncology, with the aim of improving patient care.

## CONTRIBUTION



The International Clinical Research Center at St. Anne's University Hospital will contribute to the establishment and development of Cancer Mission Hub in Czech Republic in collaboration with the other czech partners in the project.

## EXPECTATIONS



We expect to be able to engage in lay presentations and discussions for citizens, as well as national authorities, regulators, industry, patient organizations, and academia in order to raise the awareness of cancer costs in the community. At the same time, we will promote the creation of Czech CMH.



**Giancarlo Forte**  
Principal Investigator



**Sofia Morazzo**  
**Faes**  
Investigator

## CZECH REPUBLIC



# Ústav hematologie a krevní transfuze (UHKT) Institute of Hematology and Blood Transfusion



The Institute of Hematology and Blood Transfusion (IHBT) is an expanding centre offering state-of-art medicine and top-notch research, as well as a friendly and safe organization for both patients and personnel. The IHBT provides cutting-edge diagnosis and treatment of adult patients with severe disorders of hematopoiesis. The research section in cooperation with clinical and transfusion division focuses mainly on the research of hematological tumors, monitoring of gene and protein expression in onco-hematological diseases, research of low molecular weight metabolites in the treatment, study of tumour markers, and the development of new therapeutic protocols including cellular immunotherapy. In addition, the IHBT has a large program devoted to the development, GMP manufacturing and clinical testing of original Advanced Therapy Medicinal Products (ATMPs) based on gene-engineered CAR-T cells. The Institute is also significantly involved in educational and training activities, in cooperation with 1st Medical Faculty, Charles University contributes distinctly to the scientific postgraduate education.

## CONTRIBUTION

We are prepared to provide our expertise and more intense activity in 4 aspects: 1. work with the patients' organisations (as hemato-oncology institute we are already active in the field, with very good cooperation with patients and families). 2. precision medicine uses genomic data to provide the right treatment to the right patient at the right time. 3. provide analyses and propose strategies for better availability cellular immunology therapies of hematologic disorders which are being investigated in our institute. 4. we will be also very happy to participate actively in dissemination.

## EXPECTATIONS

To continue to develop the IHBT as a top scientific and research centre of hematology and oncohematology. To intensify international collaboration and exchange the experience.



CZECH REPUBLIC



## Ústav hematologie a krevní transfuze (ÚHK)T) Institute of Hematology and Blood Transfusion (IHBT)



Ústav hematologie a krevní transfuze



**Monika  
Belíčková**  
Senior Scientist



**Jan Frič**  
Senior Scientist



**Kateřina Machová  
Poláková**  
Senior Scientist



**Jana Szabová**  
Junior postdoc



**Lucie Janstová**  
Ph.D. student



**Viktor Kratochvíl**  
Coordinator of grant projects

## DENMARK

### Sygehus Lillebælt, Onkologisk afdeling, region syddanmark (SLB) Department of Oncology, Vejle, Lillebaelt Hospital, Region of Southern Denmark



Lillebaelt hospital's vision and focus: prevention of cancer is one of the hospital's primary focus areas for the future including both primary, secondary, and tertiary prevention services. As a hospital, we are focused on the fact that prevention is something we create together, across sectors. Therefore, we are working towards becoming a Clinical Center of Excellence in Prevention within the next 3 years, fostering a holistic approach to prevention that ensures addressing of all individual needs. The Clinical Center of Excellence will also be building on the hospital's concrete experiences from what is already implemented.

Denmark's national cancer patient pathways were developed at Vejle Hospital. Therefore, we are also among the first to consider prevention in conjunction with the systematic national cancer pathways. Furthermore, we are developing algorithms for risk stratification and early detection conducting research at the highest international standard. Additionally, we have an established Competence Center for Late Effects After Cancer that focuses on a holistic approach meaning that everyone has a good life with and after cancer.

All efforts are planned and implemented in collaboration with general practitioners, municipalities, and civil society. Our ambition is that all patients experience an integrated healthcare system where there is always transparency and responsibility for the patient's next steps. All prevention services are tailored in close dialogue with the patient, taking into account their desires for quality of life, capacity, and supportive networks. While some interventions are digital, others are face-to-face.

#### CONTRIBUTION

With extensive experience in Joint Actions (as work package leader, task leader, subtask leader and specific pilot activities in JA PreventNCD, EUnetCCC, JANE2, and eCANplus)) as well as future experiences within evaluation design and quality and capacity building, the Oncology Department at Lillebaelt Hospital is a key player in reducing cancer inequality in Europe.

At Lillebaelt Hospital, it is in our core, as a medium-sized hospital in Denmark, to collaborate and create partnerships. This includes University hospitals, smaller hospitals, research institutes, Universities, municipalities, general practitioners, NGOs (e.g. Danish Cancer Society), etc.

At the hospital, we have a unique test setup where we are able to develop and test new solutions across specialties and departments ensuring that our intervention benefits as many patients as possible. In the context of prevention, we continuously have a focus on alcohol consumption and smoking cessation and do intensive work in collaboration with the surrounding community including municipalities, general practitioners and the Danish Cancer Society. At Lillebaelt hospital, we approach smoking cessation as part of the treatment and tailor our approach accordingly in shared decision-making dialogue with patients.

## DENMARK



### Sygehus Lillebælt, Onkologisk afdeling, region syddanmark (SLB) Department of Oncology, Vejle, Lillebaelt Hospital, Region of Southern Denmark



#### EXPECTATIONS (CONT.)



##### Collaborative Research and Innovation

- Engage in multidisciplinary research projects to develop new methods for cancer prevention, diagnosis, and treatment, at the same time strengthen, and build cross-country relationships.
- Contribute to cutting-edge clinical trials and innovative therapeutic approaches.
- Share knowledge and resources with other institutions to foster a collaborative research environment.
- Lead programs to raise awareness about cancer prevention and early detection.
- Provide educational resources for patients and families to navigate cancer treatment and care.
- Contribute to improving health literacy by promoting healthy lifestyle choices and increase focus on preventive measures.

##### Enhanced Patient Care

- Implement advanced, evidence-based practices to improve patient outcomes and quality of life.
- Focus on personalised medicine to tailor treatments to individual patient needs.
- Ensure comprehensive care, including physical, emotional, and psychological support for patients and their families.

By participating in EU programs such as the ECHoS Mission on Cancer, our Department of Oncology is committed to advancing cancer research, improving treatment methodologies, and enhancing patient care.



**Torben Frøstrup  
Hansen**

Head of research, Chief  
consultant, Professor, PhD,  
DMSc



**Brit Sandgren**  
EU project manager

## FINLAND



### Suomen Syöpäyhdistys (CSF) Cancer Society of Finland



Cancer Society  
of Finland

The Cancer Society of Finland is one of the Finland's largest patient and public health organisation as well as being an expert organisation nationally. The CSF's work is influential in society and proficient in its field.

#### CONTRIBUTION



WP3.2 Creation of an interactive tool for stakeholder engagement.

WP5.3 Strategic Roadmap for a sustainable European network of cancer mission hubs.

#### EXPECTATIONS



The strategy of the Cancer Society Finland is to act decisively to promote health, prevent cancer, support people with cancer and to reduce adverse effects. Cancer strategy and all the supporting efforts towards that are needed in Finland and Europe.



**Juha Pekka  
Turunen**  
General Secretary



**Janne  
Pitkäniemi**  
Director of Finnish Cancer  
Registry



**Marika Skyttä**  
Director of Health  
Department



**Kirsi Talala**  
Senior Specialist, PhD

## FINLAND



# Suomen kansallinen syöpäkeskus Finlands nationella cancercentret Finnish Cancer Center



FICAN is a network of regional cancer centres all around Finland on a mission to ensure equal and high-quality cancer care, to improve prevention, diagnostics, and rehabilitation, and to support cancer research.

### CONTRIBUTION



We are responsible for the Task 3.2 of creating an interactive tool for stakeholder engagement at MS/AC, Regional and local level within the WP 3 “Multi-stakeholder identification, engagement, and cooperation” to support developing sustainable network, communication, dissemination and citizen engagement.

### EXPECTATIONS



Progression of the objectives of Mission Cancer and generation of the National Cancer Mission Hub in Finland.




**Tomi Mäkelä**

Director, Finnish Cancer  
Center



**John Eriksson**

Infrastructure integration




**Mirjami Tran**

**Minh**

Senior Planning Officer

## FRANCE



# Institut National du Cancer (INCa) French National Cancer Institute



The French National Cancer Institute (INCa) is the French government expertise agency responsible for coordinating actions to fight cancer. INCa's ambition is to provide an integrated vision covering all fields of intervention: prevention, screening, care, research and quality of life.

## CONTRIBUTION



The Institute is particularly involved in building the blueprint for the future European Network of Cancer Mission Hubs (WP5) and establishing it within the EU Cancer ecosystem (WP4).

## EXPECTATIONS



INCa hopes that the future Network of Cancer Mission Hubs will facilitate synergies between the objectives of the EU Cancer Mission and the national level of each Member State. The hubs should facilitate the engagement of all stakeholders in national research and innovation communities and health systems, and organize citizen engagement at local level.



**Thomas Dubois**

Head of the Mission for  
European and International  
Affairs



**Solène Trévidic**

EU Affairs Manager

## GERMANY



### DLR-Projektträger (DLR-PT) DLR Project Management Agency



DLR Projektträger offers comprehensive, knowledge-based services related to the management of research, education and innovation. It advises on strategies and programs, manages accompanying dialog processes, and plans and takes over the operational implementation of funding programs. The range of topics include education, equal opportunities, health, society, innovation, technology, environment and sustainability as well as European and international cooperation. In health, DLR-PT mainly works for the Federal Ministry of Research and Education (BMBF) as well as the Ministry of Health (BMG).

#### CONTRIBUTION

In 2019 the Ministry of Research and Education has launched the so-called “National Decade against Cancer” in Germany (<https://www.dekade-gegen-krebs.de/en>). For the governance, a Steering Committee has been established, composed of all relevant national players in the field of cancer (e.g. patients, policy, research, care, providers, industry, regulation). In addition to its national duties, this Steering Committee will also act as the national cancer mission hub for Germany. DLR-PT has been mandated by BMBF to share the German experiences and provide insights into how to shape National Cancer Mission Hubs in other countries.

#### EXPECTATIONS

We hope that over the next three years by sharing knowledge and smart planning it will be possible to develop a cohesive European network of National Cancer Mission Hubs with relevant impact for the European Commission’s Cancer Mission as well as for the cancer-related national and regional activities.



**Hubert Misslisch**



**Isabel Aller**



## GREECE



### ETHNIKO KENTRO TEKMIRIOSIS KAI ILEKTRONIKOU PERIECHOMENOU (EKT)



NATIONAL DOCUMENTATION CENTRE

EKT ([www.ekt.gr](http://www.ekt.gr)) is a public organization, under the auspices of the Ministry of Digital Governance, with a mission to make scientific knowledge accessible to all, operating as a knowledge hub for stakeholders oriented towards the digital economy and innovation. Having multiple roles, EKT is a) the National Authority of the Hellenic Statistical System for European statistics of Research, Development and Innovation, and b) NCP for Horizon Europe Cluster Health and Cancer Mission. Also, EKT can coordinate R&I on cancer, being a one-stop-shop service provider for SMEs, start-ups, research and innovation teams and organisations. Public and private stakeholders, as well as citizens, will be engaged in collaborative initiatives and policy dialogues on cancer, at national, regional and local level, via the creation of National Cancer Mission Hub.

### CONTRIBUTION



EKT is the leading task partner on the implementation of synergies at the operational level with key EU initiatives in the field of cancer. To ensure a seamless implementation of synergies at all (national, regional and local) levels, this task will develop an interactive Toolkit on Synergies. The toolkit will be regularly updated and will include the mapping of all relevant initiatives as well as their research outputs. It will also include a guide on how to translate outputs into actions, training events and material, workshops, knowledge exchange and research programmes, funding opportunities, policy promotion events etc. Synergies should translate into collaborative efforts/activities for the National Mission Cancer Hubs according to their priorities and needs.

### EXPECTATIONS



Through the establishment of transnational communication and collaboration networks, the project will enable the alignment of the goals of the Cancer Mission at the national level. Also, it will help bridge potential gaps between citizen (and patient) participation and the formulation and implementation of cancer policy. All involved stakeholders will increase their recognition, and ease penetration in the health sector, alongside increased access to new technologies in order to provide holistic services. Additionally, populations in all EU members states and associated countries will benefit from information sharing and participation in relevant policy dialogues. Wider benefits can also be foreseen for all stakeholders, including the Greek innovation ecosystem through e.g. increased awareness of potential technological breakthroughs and synergies between physicians, policymakers and patients.



GREECE



ETHNIKO KENTRO TEKMIRIOSIS KAI  
ILEKTRONIKOU PERIECHOMENOU (EKT)



NATIONAL DOCUMENTATION CENTRE



**Sofia Xesfingi**

Project Manager



**Angelos**

**Angelidis**

Expert Innovation  
Consultant

## HUNGARY



### Országos Onkológiai Intézet (OOI) National Institute of Oncology (NIO)



The NIO is the only OEI accredited Comprehensive Cancer Center in Hungary with 14 clinical and diagnostics and 6 research departments, 347 beds and staff of more than 1,300 employees focusing on cancer care, research and education. It is the coordinator of the Hungarian Oncology Network, and manages the National Cancer Registry.

#### CONTRIBUTION



The NIO is a stakeholder in many EU initiatives such as the EUnetCCC (WP3 Co-Leader), JANE 1-2, OriON, CCI4EU, eCAN+, GDI, PCM4EU, Prime-Rose, and the latest JA PCM and CancerWatch projects, among others. NIO also contribute to the objectives of WP2, WP4 and WP6 of the ECHoS.

#### EXPECTATIONS



The NIO, as the coordinator of the Hungarian Oncology Network is looking forward to contributing to the development of the National Cancer Mission Hubs and to reach the goals of the ECHoS project in a pan-European manner.



**Péter Nagy**  
Principal Investigator



**Edit Marosi**  
Team member



**Réka Felhő**  
Team member



**Gergely Csaba  
Horváth**  
Team member

IRELAND



National Cancer Control Programme,  
Health Service Executive (NCCP, HSE)



The NCCP works with partners in Ireland to prevent cancer, treat cancer, and increase survival and quality of life for those who develop cancer, by converting evidence and knowledge into strategies and actions.

CONTRIBUTION

The NCCP will work with our partners nationally and across Europe to lay the foundations for a Cancer Mission Hub that will be meaningful for the people of Ireland and builds on the expertise of our European colleagues.

EXPECTATIONS

We hope that the next three years will be a collaborative experience to collectively contribute to cancer services in our respective countries and provide a roadmap for greater citizen engagement in cancer policy and service development.



**Risteárd Ó Laoide**  
National Director, National  
Cancer Control Programme



**Donal Brennan**  
National Clinical Lead for Cancer  
Research, National Cancer Control  
Programme and UCD Professor of  
Gynaecological Oncology, Mater  
Misericordiae University Hospital



**Ruth Ryan**  
National Cancer Control  
Programme



**Ciara Mellett**  
National Cancer Control  
Programme



**Ozlem McDonnell**  
National Cancer Control  
Programme (Project  
Coordinator)

## IRELAND



### All-Island Cancer Research Institute (AICRI)



AICRI ([www.aicri.org](http://www.aicri.org)) builds an overarching framework for cancer research across the island of Ireland. It involves 11 academic institutions and stakeholders, covering prevention, diagnosis, treatment, and survivorship.

#### CONTRIBUTION



Together with the National Cancer Control Programme (NCCP) of Ireland, AICRI co-leads Ireland's NCMH design, contributes to WP Outreach & Events, fosters EU collaborations, and strengthens all-island networks aligning research, policy, clinical care, and citizen engagement.

#### EXPECTATIONS



Advance Ireland's NCMH with NCCP, deepen EU collaborations, boost all-island outreach and knowledge-sharing, and build synergies with EU cancer initiatives and the evolving NCMH network.



**William  
Gallagher**

AICRI Co-Lead & Professor of  
Cancer Biology, University  
College Dublin



**Chantal Halley**

Programme and  
Engagement Manager (All-  
Island Cancer Research  
Institute)



**Shashank  
Srinivas**

Irish Cancer Society AICRI  
Research Analyst (All-Island  
Cancer Research Institute)

## ISRAEL



### לשכת המדען הראשי - משרד הבריאות (CSO-MOH) Israeli Ministry of Health – Chief Scientist Office



The Ministry of Health is responsible for ensuring the health of the population. It establishes policies related to health care and medical services and oversees the planning, supervision, control, licensing, and coordination of the health care system. The Chief Scientist's Bureau represents the Ministry of Health in EU-funded life sciences and medicine research networks, supporting Israeli researchers collaborating with European partners. It maintains ongoing connections with research institutions and national and international research-supporting organizations.

#### CONTRIBUTION



CSO-MOH will support WP2 activities related to capacity building and knowledge exchange. In addition, we will participate in WP3, contributing to efforts that promote the implementation of the Cancer Mission.

#### EXPECTATIONS



We look forward to the opportunity to visit and gain firsthand insight into how NCMHs operate in other countries. We plan to foster collaboration between national stakeholders including the National Council for the Prevention, Diagnosis, and Treatment of Malignant Diseases to exchange data and expertise to contribute to ECHoS and EU efforts on mission cancer.



**Irit Allon**

Head of the Department of  
Medical Research



**Ido Wolf**

Director of the Oncology  
Division Ichilov Hospital,  
Chairman of the National  
Council for the Prevention,  
Diagnosis, and Treatment of  
Malignant Diseases



**Netta Koren**

ERA-Net /JPI National  
Coordinator



**Namma**

**Yaroslaviz**

ERA-Net /JPI National  
Coordinator

## ITALY



### Università Cattolica del Sacro Cuore (UCSC)



UNIVERSITÀ  
CATTOLICA  
del Sacro Cuore

The Università Cattolica del Sacro Cuore ([www.unicatt.it](http://www.unicatt.it)), founded in 1921, includes five campuses (Milano, Brescia, Piacenza-Cremona, Roma). The School of Medicine in Rome is at present a world-class training ground for future leaders in medical research and practice, public health and biomedical science.

#### CONTRIBUTION

UCSC will actively work on Task 4.2 to map and continue synergizing with relevant EU and international initiatives in the field of Cancer and Cancer Research.

#### EXPECTATIONS

UCSC's objectives within the ECHoS project are to promote synergies between projects and institutions aimed at fighting cancer in Europe. Over the three-year project period, the aim is to identify as many active projects, possible contact-points and synergies in order to optimise efforts in this area.



**Stefania Boccia**  
Coordinator



**Roberta  
Pastorino**  
Senior Researcher



**Laura Motta**  
Grant Advisor



**Tommaso Osti**  
Junior Researcher



**Giorgia  
Perazzoni**  
Junior Researcher



**Abdelrahman  
Taha**  
Junior Researcher

## ITALY



### Alleanza Contro Il Cancro (ACC) Alliance Against Cancer



ACC is an Italian oncology research network founded in 2002 by the Ministry of Health. The network includes many comprehensive patient care and research institutes (IRCCS), associations and foundations, and the Italian National Institute of Health, which hosts its offices. The mission of ACC is to bring technological and organizational innovation from basic cancer research to clinical practice, raising and unifying the level of care, treatment, and rehabilitation of cancer patients throughout the country.

#### CONTRIBUTION

ACC will actively contribute to Task 4.2 - Operational level synergies with EU initiatives - in coordination with UCSC, and will participate in the activities led by INT for Task 2.1 - Definition of general design and operative NCMH structural elements.

#### EXPECTATIONS

Contributing to shape the identity of National Cancer Mission Hubs and to leverage existing national assets that align with NCMH objectives.



**Lidia Villanova**  
Scientific Project Manager



**Valentina Trapani**  
Scientific Project Manager



## ITALY

# Fondazione IRCCS Istituto Nazionale dei Tumori (INT) National Tumours Institute, Milan



Fondazione IRCCS  
Istituto Nazionale dei Tumori

Sistema Socio Sanitario



Regione  
Lombardia

INT is a public center for treatment and research (IRCCS) and an OEI-certified Comprehensive Cancer Center since 2015 with activities ranging from cancer diagnosis and care to clinical, basic, translational and epidemiological research. INT is the first Italian center in the Ministry's ranking for healthcare activities and research productivity indicators. In ECHOS INT avails itself of the support of 3 third parties, Fondazione The Bridge, Fondazione Don Gnicchi ONLUS and Fondazione Regionale per la Ricerca Biomedica.

## CONTRIBUTION

INT will lead WP2, in particular aimed at (1) mapping of the current European landscape regarding the presence, structure and activity of National Cancer Mission Hubs as well as (2) design a set of minimal criteria to define what is a NCMH: its components, their interactions and the Hub's objectives tailored to the national situation.

## EXPECTATIONS

INT's expectations are twofold – we look forward on the one hand to support the definition of policies and guidelines to enhance the impact of the Mission in Europe ; on the other, we hope that the project can help further and strengthen the interaction between the research world and policy actors at the Italian level, improving already-existing Hub-like structures.



**Giovanni  
Apolone**

INT's Scientific Director



### Scientific team:

Annalisa Trama (JA JANE  
coordination team)

Luca Roz

Arsela Prelaj

Rosalba Miceli



## ITALY



### Fondazione The Bridge (FTB) The Bridge Foundation



Fondazione The Bridge is an independent non-profit organisation for the protection of the right to health. It acts as a bridge between institutions and scientific, clinical organisations, industry and patients associations.

#### CONTRIBUTION



FTB will contribute, within WP3.2 to the engagement of relevant traditional and non - traditional, organised and non-organized stakeholders, including citizens and patients in the policy dialogue on cancer in Italy, and offer support in the creation of the interactive tool for stakeholder engagement.

#### EXPECTATIONS



FTB expectation is to be able to stimulate the systemic engagement of national and subnational stakeholders through a continuous expanding of the Italian network of stakeholders in the policy dialogue on cancer.



**Rosaria Iardino**



**Chiara Crepaldi**



**Luisa Brogonzoli**

## ITALY



### Fondazione Don Carlo Gnocchi ONLUS (FDG) Don Carlo Gnocchi Foundation



FDG is a non-profit, private foundation, accredited through the National Health Service in 28 centres distributed over 9 Italian regions and since 1991 and as a “Scientific Institute for Research, Hospitalization and Health Care” (It. IRCCS) by the Italian Ministry of Health, with the specializations in bio-medicine, biotechnology and clinical experimentation for rehabilitation and reducing disability conditions.

#### CONTRIBUTION

FDG will contribute to the project as third party of the partner Fondazione IRCCS Istituto Nazionale Dei Tumori (Int), within WP2 and WP3, supporting the enhancement of pre-habilitation and oncological rehabilitation in the domain of the Cancer Missions Hubs.

#### EXPECTATIONS

FDG expectation is to be able to contribute to the definition of guidelines and policies to enhance in the healthcare system protocols for pre-habilitation (e.g. cancer pre-surgery) and for oncological rehabilitation (e.g. to fast recovery or to co-aid pharmacological therapies).



**Paola Gabaldi**  
Research Managing Director



**Lorenzo  
Brambilla**  
Cardiologist, Medical  
Director



**Alessandro  
Viganò**  
Neurologist, Clinical  
Researcher

## ITALY

### Fondazione Regionale Per La Ricerca Biomedica (FRRB) Regional Foundation For Biomedical Research



Founded in 2011 by Lombardy Region, Fondazione Regionale per la Ricerca Biomedica (FRRB) represents one of the main strategic platforms for boosting progress, research, development and innovation in hospitals, universities and research centres focused on biomedical research.

#### CONTRIBUTION

FRRB will act as Istituto Nazionale dei Tumori (INT) third party, supporting INT to strengthen the regional and national networks.

#### EXPECTATIONS

FRRB will provide all support needed to establish a stronger ECHOS network, ensuring the visibility of the outcomes of the projects among policy makers and involved stakeholders.



**Giulia Maria  
Rossignolo**  
EU project manager

## LATVIA



### Rīgas Austrumu klīniskās universitātes slimnīca (RAKUS) Riga East University Hospital – REUH



Riga East University Hospital (REUH) is the largest emergency multi-profile healthcare institution in Latvia and comprises from 5 clinical centres: Clinical Centre of Emergency Medicine „Gailezers”, Oncology Centre of Latvia, Clinical Centre „Bikernieki”, Latvian Centre of Infectious Diseases, and Centre of Tuberculosis and Lung Diseases.

REUH fields of expertise are microsurgery, plastic and reconstructive surgery, bed sore treatment, toxicology, and sepsis, polytrauma, burn and frost-bite treatment, stem cell transplantation, tuberculosis, HIV/AIDS treatment, and stereotactic radiation therapy for oncology patients.

The oncology care in REUH is provided by all 5 clinical centres according to clinic specialization and cancer type. From all oncological conditions in Latvia approximately 85% of the solitary tumours and 98% of onco-haematology patients are treated at the REUH. REUH provides all types of the cancer treatment – cancer surgery, chemotherapy, and radiation.

There are several specialized clinics in REUH – Oncological Surgery clinic (breast cancer, abdominal surgery, gynaecology, ENT oncology) clinic, Radiation Therapy clinic, Chemotherapy and Haematology clinic. Also, there is Haematology transplantation clinic in REUH, where analogue stem cell transplantations and allogeneic family donor transplantations are performed.

REUH has started an accreditation process for Cancer Centre to become in the nearest future accredited Cancer Centre and after aiming to become Comprehensive Cancer Centre. REUH is also actively establishing cooperation with partners from Estonia, Lithuania, Poland, and Hungary.

## CONTRIBUTION



To ensure the successful implementation of the Cancer Mission, Aslimnica will engage in all ECHoS activities to successfully integrate ECHoS activities at Latvian national level in the future.

## LATVIA



Rīgas Austrumu klīniskās universitātes slimnīca (RAKUS)  
Riga East University Hospital – REUH



### EXPECTATIONS



To receive an opportunity to participate in cohesive, structured, and communicative network of NCMHs, for collaborative research, systemic ECHoS' organization engagement to exchange best practices.



**Alinta Hegmane**  
Oncologist Chemotherapist



**Andrejs Pcolkins**  
Head of Abdominal and Soft  
Tissue Surgery Department



**Rimma Berzina**  
Project Manager

## LATVIA



# Latvijas Universitāte (LU)

## The University of Latvia



**LATVIJAS  
UNIVERSITĀTE**

LU has a broad experience in implementation and management of nationally, EU level and internationally funded research projects and well-developed and organized administrative structure for project management and implementation.

The Institute of Clinical and Preventive Medicine of the University of Latvia (LU ICPM) is among the leading research institutes of Latvia to bridge basic medical research to the clinics. The main areas of research include gastrointestinal cancer prevention and screening, infectious diseases, the role of microbiome in health and disease, new technologies and biomarkers for detection, screening, monitoring of various diseases, including cancer and infectious diseases.

The Institute has a long-standing expertise in running biobank, including enrolment of cancer patients, and a relevant group of control. It is the leading chain in clinical medicine within the national node of the BBMRI infrastructure.

LU ICPM has developed broad international collaboration in Europe, Asia, United States and Latin America, East Europe and central Asia. LU ICPM has initiated and currently supporting IARC in realization of the project "Improving cancer care coordination and screening in Latvia and Slovakia". LU ICPM has developed strategic partnerships with multiple clinical institutions and facilities, and is running study subject facilities in these institutions.


## CONTRIBUTION

LU ICPM has developed strategic partnerships with multiple clinical institutions and facilities, and is running study subject facilities in these institutions. Riga East University hospital (REUH), being the reference centre for oncology is the main of these strategic partners. About 80% of all the cancer patients are seen in this hospital (Latvia Oncology Centre is a part of this hospital). Our participation in the Consortium would complement the geographical reach in Northern Europe by including one of the leading research institutes in this field in Latvia and our partner - the largest oncology centre in the country. We would contribute to the incorporating points relevant for our country/region.



**Ilmārs Stonāns**

Deputy Director at Institute  
of Clinical and Preventive  
Medicine



**Dina Bēma**

Researcher at ICPM

## LITHUANIA



### Lietuvos mokslo taryba (LMT) Research council of Lithuania (RCL)



Research  
Council of  
Lithuania

Research Council of Lithuania (RCL) is a science and studies policy-implementing institution, which performs an expert and advisory function to the Seimas of the Republic of Lithuania and to the Government in matters of studies and experimental development. RCL's mission – is to actively participate in the formulation of research, experimental development, and innovation policy and to strive to make Lithuania's system of research, experimental development and innovation effective and in line with the expectations of Lithuanian society and global challenges, by applying organisational and financial instruments for competitive funding of scientific research. The overarching goal of the RCL is to increase the value, efficiency and impact of science. This is achieved by developing activities along the following main axes: to make science funding more efficient, develop Lithuania's scientific community, implementing the principles of open science, as part of Lithuania's science policy.

#### NATIONAL NCMH-LIKE STRUCTURE



RCL: perform an expert function, conducting scientific performance evaluations, administers the most important programmes for the development of Lithuanian science, represents Lithuania's interests in science and experimental development issues in working groups of the European Union member states and in many international organisations, implements competitive funding for science programmes.

#### CONTRIBUTION



Main LMT contribution is in 3 WP Task 3.2 Identify stakeholders and create an interactive tool for stakeholder engagement at MS/AC, regional and local level (M1-M30) and in other tasks where participates all members.

#### EXPECTATIONS



Active participation in the establishing a network of National Cancer Mission Hubs in national level and in the connection of these hubs transnationally.



**Laura Pėkienė**

Project manager, main  
contact person



**Sigita Auvertin**

Manager (assistant),  
secondary contact person



## LITHUANIA



### Klaipėdos universitetas (KU) Klaipeda University



Klaipėda University (KU) is one of the leaders in the fields of interdisciplinary research and studies both in the national level and Baltic Sea Region. Integrated in a unique way health sciences are consistently and systematically developed in one of the KU academic units - The Faculty of Health Sciences (FHS) Integrated interdisciplinary research is conducted to strengthen public health, social well-being and a sustainable community. Here is implemented a high-level fundamental and applied studies and (social) development activities through an integrated teaching/learning process. The research carried out by the FHS meets one of the priorities of the EU's strategic programme HORIZON 2020 "Health, Democratic Change and Prosperity", as well as one of the objectives of the EU Baltic Sea Strategy Action Plan "Sustainable and Healthy Society". Scientists at the FHS are leaders in the field of research result implementation in practice, influencing changes in health and social science research, linking knowledge in these fields, and proposing innovative solutions for integrated social well-being. The Health Research and Innovation Science Center is Unit of Faculty of Health Sciences in Klaipėda University, which was established by the implementation of the University's strategy to strengthen the interdisciplinary health research. The Center provides a high-level fundamental and applied research and experimental development work, integrated education and learning process.

#### CONTRIBUTION



Research performer, education and training.

#### EXPECTATIONS



Creation of sustainable NCMHs, and help NCMH engage in collaborative work with individual European Initiatives as well as help in creating conditions for NCMHs to be Mission Cancer advocates in MS/AC in Lithuania.



**Alona Rauckiene-  
Michaelsson**

Lead



**Cesar Agostinis-  
Sobrinho**

Co-Lead



**Narimantas  
Samalavičius**

Team Member



## LITHUANIA



### Lietuvos Sveikatos Mokslu Universitetas (LSMU) Lithuanian University Of Health Sciences



Lithuanian University of Health Sciences (LSMU) is the largest institution of higher education for biomedical sciences in Baltic region and Lithuania also one of the largest universities in Europe specializing in health sciences. With over 30 years of international experience LSMU is successfully combining integrity of teaching, clinical practice and research, competence based education together with multicultural dimension. LSMU's mission is to create, accumulate, systematize, and disseminate scientific knowledge, the latest achievements in research and education, to teach and educate creative, honest, enterprising, educated, healthy, independent, and entrepreneurial personalities, to foster democracy and prosperity, and to nurture a healthy and well-educated society. The exclusive role of LSMU in this educational process is the pursuit of a healthy society, guaranteeing the social and economic progress of the country, the civilisational identity of Lithuania, the creation, fostering and development of cultural traditions of the country and the world. The health and welfare of animals is an integral part of this aspiration.

LSMU studies take place in 81 Departments of Research and Science: 4 Research Institutes, 20 Departments, 48 Clinics, 9 Faculty Institutes. The University community consists of nearly 3,000 employees. LSMU has 2 affiliated medical hospitals: Hospital of LSMU Kauno klinikos (the biggest health facility in Lithuania) and the LSMU Kaunas Hospital. Medical teaching and research are mainly based on cooperation with affiliated medical clinics.

The field of Oncology is one of the most developing directions of the LSMU. The Institute of Oncology conducts scientific research and experimental development activities of strategic importance to the University, delivers courses under the respective study programmes, and trains prospective researchers.

## CONTRIBUTION



Lithuanian University of Health Sciences is ready to actively cooperate in the implementation of the "Mission Cancer Hubs" project, by working together with scientific and clinical institutions and ensuring active public involvement. Our main focus will be on creating Advisory Board for knowledge exchange, communication, dissemination and cooperation with the EU and other stakeholders. To ensure the success of the project and public awareness, LSMU will organize awareness events of "Mission Cancer Hubs" in cooperation with patient organizations and the media. Also, we are willing to participate in the development of "Health Policy" and "Health Research Programs". And of course, we certainly do provide technical assistance to researchers and members in the further development of the project.

## LITHUANIA



### Lietuvos Sveikatos Mokslu Universitetas (LSMU) Lithuanian University Of Health Sciences



## EXPECTATIONS



The project is expected to facilitate the exchange of information and knowledge and best practices between participating countries. will be created a platform for the development and implementation of national cancer strategies. The project will encourage the development of innovative approaches to cancer treatment, such as the use of digital health solutions and the integration of care across multiple services. "Mission hubs" will promote awareness and public involvement in solving cancer problems. As a result, the quality of life, physical and psychological health of patients and their relatives will improve.



**Elona Juozaityte**

Radiation Oncologist, Senior  
Expert, Manager in ECHoS  
Project




**Rita Kupcinskaite  
– Noreikiene**

Medical Oncologist,  
Specialist in ECHoS Project



**Agne  
Dorelaitiene**


Administrator in ECHoS  
Project



**Erika  
Korobeinikova**

Radiation Oncologist

## LITHUANIA



### Lietuvos sveikatos mokslų universiteto ligoninė Kauno klinikos Hospital of Lithuanian University of Health Sciences Kauno klinikos



The Hospital of Lithuanian University of Health Sciences Kauno klinikos is the largest hospital in Lithuania. Established in 1940, Kauno klinikos has grown into one of the most prominent and modern hospitals in the country. The hospital of Kauno klinikos is dedicated to providing the highest quality healthcare to patients from all over the country and abroad. There are many medical "first" and "only" performed in Kauno klinikos which shows a high level of professionalism, qualification, modern medical technologies, and developed infrastructure implemented in the hospital. Kauno klinikos has 39 departments devoted to all medical and surgical specialties. Here the most serious, rare, and undiagnosed diseases are successfully diagnosed and treated, and extremely complex operations are performed.

#### CONTRIBUTION



Kauno klinikos will especially contribute to ECHoS project in the areas of communication, dissemination, and participation. In order to ensure the success of the project, researchers from Kauno klinikos have been appointed to implement project's objectives by validating project ideas and contributing to knowledge exchange. Main contribution of Kauno klinikos will be in WP1, WP2 and WP6.

#### EXPECTATIONS



It is expected that the creation of National Cancer Mission Hubs (NCMHs) will provide a space for the exchange of information and knowledge between the different stakeholders involved in cancer care. Additionally, the implementation of the Cancer Mission objectives will promote more resilient and people-centric healthcare and research systems.



**Rasa Jančiauskienė**  
Medical oncologist, lead in ECHoS project



**Lina Pužauskienė**  
Medical oncologist,  
specialist in ECHoS project



**Agnė Kairaitytė**  
Project coordinator in ECHoS project

## LUXEMBOURG



### Institut National du Cancer (INC) National Cancer Institute



Institut  
National du  
Cancer

The INC is an association without lucrative purpose. Its activities cover among others the overall organization of oncology, the development of cancer care pathways and guidelines, the promotion of the centres of competence.

#### CONTRIBUTION



The institute, as beneficiary partner, will have a role in the communication, dissemination, and engagement of the project, as well as in policy maker or regulator, including standardisation body activities.

#### EXPECTATIONS



INC intend to support the implementation of the Cancer Mission and the integration of activities at national level through engagement of relevant stakeholders (by providing NCMHs with guidelines & best practices).




**Guy Berchem**  
Expert



**Nikolai  
Goncharenko**  
Coordinator



**Amélie Gaignaux**  
Head of EU collaborations



**Fellahi Mehdi**  
EU Project Manager

## LUXEMBOURG



# Luxembourg Institute of Health (LIH)

Luxembourg Institute of Health



The LIH is a public research organisation, which defines cancer as a priority and covers research from fundamental, mechanistic research to translational patient-based preclinical research to clinical studies and trials.

### CONTRIBUTION

LIH will contribute to ECHoS by establishing bridges with other EU bodies or initiatives, and by broadening engagement in Cancer Mission activities, and empowering NCMH structures through the organization of transnational events.

### EXPECTATIONS


LIH expects to build on the establishment and development of a national CMH in parallel of its national initiative of a National Centre for Translational Cancer Research, involving all national stakeholders in oncology.



**Tatiana Michel**

Strategic Program Manager

## MALTA



### Xjenza Malta



Xjenza Malta (Science Malta) established by means of Legal Notice 112 of 2024, is the Malta Government Agency acting as the national R&D and Space-funding agency, and the policy development and implementation body in the area of Research, Innovation and Space. Science Malta is entrusted with the updating of the national R&I and Space policy frameworks, overseeing and coordinating R&I and Space-strategy implementation through programming efforts, including the direct management of the national public budgetary allocation for Research, Innovation and Space. Science Malta manages and implements the FUSION portfolio, thus financing research endeavours across the entire technology-readiness spectrum, providing a multi-million portfolio primarily via grant-based support. Science Malta also hosts the National Contact Point (NCP) network for Horizon Europe, promoting and ensuring Malta's overall successful participation in the EU Framework Programme for R&I and related support schemes, while also representing the Government of Malta within the comitology structure of Horizon Europe.

### CONTRIBUTION



Xjenza Malta is the Work Package Leader of WP4 on Synergies: Bridges to other Missions and European Initiatives. In this work Package, Xjenza Malta will champion the dialogues happening in different fora and ensure that the new concept of Cancer Mission Hubs is taken up in such dialogues. Furthermore, Xjenza Malta is leading a task also in WP4 relating to ensuring a 'cancer-in-all' approach.

### EXPECTATIONS



Xjenza Malta is very happy to be part of this consortium and looks forward to collaborating with the many partners collaborating in this project. We will be working closely with the Ministry for Health (also a partner in the project) to set up a meaningful National Cancer Mission Hub to ensure a good outreach of the Cancer Mission among our communities.



#### Ian Gauci Borda

NCP HEALTH, Research  
Infrastructures and  
Widening

## MALTA



### Ministeru tas-Saħħa Ministry for Health and Active Ageing (MHA)



GOVERNMENT OF MALTA  
OFFICE OF THE DEPUTY PRIME MINISTER  
MINISTRY FOR HEALTH

The Ministry is one of the Ministries of the Government of Malta and it is responsible for the national health system in Malta.

#### CONTRIBUTION




The Ministry will contribute through its national perspective as the policy maker and provider of health services to the people residing in the Maltese Islands.

#### EXPECTATIONS



The influence the design and creation of National Cancer Hubs within ECHoS so that they can be able to include different models that can suit the different contexts of the different Member States within Europe.



**Miriam Dalmas**

Main coordinator



## NETHERLANDS

### Integraal Kankercentrum Nederland (IKNL) Netherlands Comprehensive Cancer Organisation



The main goal of the Netherlands Comprehensive Cancer Organisation (IKNL), with the Netherlands Cancer Registry (NCR) as its core activity, is to reduce the impact of cancer, from the personal to the societal level.

#### CONTRIBUTION

IKNL will participate in almost all work packages. IKNL contributes to building the Dutch Cancer Mission Hub through the Netherlands Cancer Collective (NKC), an independent and inclusive collaboration of more than 140 stakeholders from within and beyond the healthcare sector. We help connect national efforts with EU ambitions, ensuring that Dutch knowledge, innovation, and data infrastructures contribute to, and benefit from, Europe's collective fight against cancer.

#### EXPECTATIONS

We expect that this collaboration i.e., sharing of information and best-practice will enhance the (trans)national implementation of cancer hubs supporting the European mission on cancer.



#### Jolanda Sinha

Project leader (Head of Communication IKNL)



#### Carla van Laer

Project participant (program manager Netherlands Cancer Collective (NKC) and IKNL)



#### Akke Albada

Project participant (Head of the executive office IKNL)



#### Manon Crijns

Project participant (teamleader advocacy), Dutch Federation of Cancer Patients Organisations (NFK) and external employee IKNL




#### Warnyta Minnaard

Project participant (project manager Netherlands Cancer Collective (NKC) and IKNL)



## NORWAY

### Kreftforeningen Norwegian Cancer Society (NCS)



NCS is one of the largest organisations in Norway, representing the voices of those affected by cancer. We work in the field of cancer prevention and care through cancer research funding, political advocacy, communication and support services.

#### CONTRIBUTION

Strategic and operational support for citizen engagement in WP 6 , including sharing and mapping best practices. Sharing experiences from our work in Cancer Mission Hub Norway on policy alignment and implementation of MoC and EBCP at national, regional, and local level.

#### EXPECTATIONS

We expect that governments on all levels, health sector, researchers, industry, patient organisations and citizens contribute in this joint effort so that MoC and EBCP become a true game changer for cancer patients, survivors and their families, in Norway and Europe.



**Astrid Bjerke**

Strategic adviser/Project participant (main contact)



**Ole Alexander Opdalshei**

Assistant Secretary General, Project participant



**Simen Enger**

Special adviser/Project participant

## NORWAY



### Oslo Cancer Cluster (OCC)



Oslo Cancer Cluster (OCC) is a national non-profit Oncology Research & Industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and treatments. Our portfolio comprises >90 members, covering the entire oncology value chain. Our recurring topics include precision medicine, immune- and cell- therapies and novel digital technologies. A dedicated Incubator team provides innovators and start-ups with business development services, access to an international network of key industry players, and advise on funding strategies.

Together with The Research Council of Norway and the Norwegian Cancer Society, OCC has put significant efforts in developing the Cancer Mission Hub Norway, since 2022.

#### CONTRIBUTION

Based on its experience working at the interface of sectors in Oncology, OCC is supporting activities in WP3 on stakeholder engagement. It includes promoting the implementation of strategies for National Cancer Mission Hubs to efficiently mobilise relevant actors in the Mission on Cancer and to foster cooperations, alignment of goals and cultures.

#### EXPECTATIONS

Contribute to an EU-wide coordinated effort that supports the acceleration of Cancer innovation for patients in Europe. Connect the Norwegian hub to the larger European network, learn from the experience of similar structures and help to build best practices.



**Ketil Widerberg**  
General Manager




**Marine Jeanmougin**  
Lead European Affairs



**Bente Prestegård**  
Project Manager

## NORWAY

### Forskningsrådet The Research Council of Norway (RCN)



RCN is a national strategic and funding agency for research activities, and a chief source of advice on and input into research policy for the Norwegian government, the central government administration and the overall research community.

#### CONTRIBUTION

The position of RCN in Norway and the Cancer Mission Hub Norway makes RCN particularly well equipped to create synergies with Norwegian and EU initiatives such as national ministries and authorities, other Missions, NCP and NFP networks, Partnerships, the TRAMI network etc.

#### EXPECTATIONS

Contribute to, and build networks. Best practices/experience sharing on how to organize successful national mission cancer hubs. Positioning of the Cancer Mission Hub Norway in Europe.



**Sofia Anderholm  
Strand**

Senior Adviser, NCP for  
Health and Missions



**Margarethe  
Biong**

Senior Adviser, NCP for  
Health

## POLAND



# Narodowe Centrum Badań i Rozwoju National Centre for Research and Development (NCBR)



National Contact Point  
for EU Research Programmes

National Contact Point for Horizon Europe (NCP Department within NCBR) supports the participation of Polish research organisations, enterprises and other institutions in the EU Framework Programme for Research and Innovation Horizon Europe.

## CONTRIBUTION



Task 3.2 Identify stakeholders and create an interactive tool for stakeholder engagement at MS/AC, Regional and local level

Task 5.1 – Define scope of the EU network of National Cancer Mission Hubs

## EXPECTATIONS



Better integration of cancer related activities at national, regional and local level; successful implementation of Cancer Mission activities in Poland; the creation of Polish Cancer Mission hub.



**Ewa Szkiladz**  
Health and Mission NCP



**Dagmara  
Robakowska-  
Hyzorek**  
Health NCP

## POLAND



### Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy Maria Skłodowska-Curie National Research Institute of Oncology (MSCI)



The Maria Skłodowska-Curie National Research Institute of Oncology is the largest and most advanced comprehensive cancer center in Poland and one of the key institutions in Central Europe. Its main headquarters is in Warsaw, with regional branches in Kraków and Gliwice. The Institute employs over 5,800 staff, including 1,300 doctors and 220 researchers. In 2024 alone, the Warsaw headquarters of the Institute recorded over 100,000 hospitalizations, more than 300 major surgeries, and ca. 500,000 outpatient visits. The Institute conducts over 500 active clinical trials in oncology, supported by the Early Phase Clinical Trials Unit (the first in Poland), the Clinical Trial Support Center, and the Center of Excellence in Precision Oncology.

The Maria Skłodowska-Curie National Research Institute of Oncology also serves as the national coordinator for the implementation of the National Oncology Strategy and the National Oncology Network, manages the National Cancer Registry, and develops national diagnostic and treatment guidelines. As a member of the EURACAN network, it is a reference center for the treatment of rare cancers. For many years, the Institute has cooperated with international organizations such as OECI, ESMO, EORTC, ESTRO, ASCO, and IARC, actively helping to shape global oncology standards.

#### CONTRIBUTION



Leader of Task 2.2 and Task 5.2. Expertise in the cancer field coming from the Experts collaborating with the leading comprehensive cancer centre in Poland. Knowledge of conducting basic research, clinical trials, postgraduate and highly specialized training and provides the most up-to-date diagnostic and therapeutic facilities. Cooperation with the Polish Ministry of Health and the Ministry of Science. Integration of the NCMH to the National Cancer Strategy in Poland.

#### EXPECTATIONS



Creating Polish Cancer Mission Hub and promoting the creation of NCMH in the country on regional and local levels, as well as being an active partner in the European Cancer Mission Network. Increase awareness and engagement of relevant stakeholders in the country in policy dialogues on Cancer as well as across Europe.

To establish a network of support to advance Cancer Mission across Europe.

To create the foundations for NCMHs by formulating recommendations on governance, business models, legal status, strategic positioning, and communication of Cancer Mission objectives across all the societies.

Coordination of all actions undertaken within Europe Beatings Cancer Plan.

POLAND



**Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy**  
Maria Skłodowska-Curie National Research Institute of Oncology (MSCI)



**Iwona Ługowska**

Head, Department of Early Phase Clinical Trials Unit, and Centre for Excellence for Precision Oncology



**Piotr Rutkowski**

Head of the Department of Soft Tissue/Bone Sarcoma and Melanoma




**Dorota Dudek-Godau**

Senior Project Specialist



**Agnieszka Janowska**

Head of International Affairs Office



**Lidia Dyndor**



**Beata Biel**

Head of the Department of Monitoring and Coordination of National Cancer Strategy

## PORTUGAL



### Direção-Geral da Saúde - Ministério da Saúde (DGS-MS) General Directorate of Health Ministry Of Health



DGS (<http://www.aicib.pt>) is a central service of the Ministry of Health of Portugal, integrated into the direct administration of the State, endowed with administrative autonomy. The DGS exercises its activity centred on the interests of citizens, in articulation and cooperation with other services and bodies, in particular those dependent on the Ministry of Health.

#### CONTRIBUTION

As an associated partner to ECHoS, DGS/MS will contribute with the perspective of a national health authority to the ECHoS project. DGS/MS will also support the dissemination of ECHoS and ECHoS' results in the national health community by engaging ECHoS partners in relevant meetings.

#### EXPECTATIONS

Expectations of DGS/MS towards ECHoS project are focused in the capacity to align European and National Policies in Health and related areas. Reducing the gap between European and National policies and actions, in health in general, is essential to secure a more robust and resilient Europe, prepared to face future challenges in health. The rise in the number of cancer cases in Europe is frightening, only coordinated actions between all countries, with high coordination between relevant stakeholders and community in general, will enable fighting cancer by reducing inequalities in literacy, access to diagnostic and treatment and quality of life of survivors. This is also a unique opportunity to align actions and strategies between EU framework Programmes of Health and of Research. It is fundamental to coordinate investments on research towards health needs, and investment on health towards research results, to guarantee a better use of resources and knowledge.

## PORTUGAL

### Direção-Geral da Saúde - Ministério da Saúde (DGS-MS) General Directorate of Health Ministry Of Health



**DGS** desde  
1899  
Direção-Geral da Saúde



Programa Nacional  
para as Doenças Oncológicas



#### José Dinis

Director for the National  
Strategy for Oncological  
Diseases



#### Isabel Fernandes

Deputy to the Director for  
the National Strategy for  
Oncological Diseases



#### Cristina Portugal

Program Manager



## ROMANIA



### Asociația Centrul Pentru Inovație În Medicină Centre for Innovation in Medicine (INOMED)



INOMED is a European non-profit research organisation with a key focus on co-creating citizen-centric, innovative health policies, as well as engaging all stakeholders through education and communication activities.

#### CONTRIBUTION

Lead for WP3: Multi-stakeholder identification, engagement, and cooperation. With contribution also in WP 2 and WP 6.

#### EXPECTATIONS

To contribute to the co-creation of a framework for NCMHs that can represent the needs of citizens and patients, and to help achieve the Cancer Mission goals at the local, national, regional, and EU levels.



#### Marius Geantă

INOMED President and  
Scientific Lead (Senior  
expert)



#### Cosmina Cioroboiu

INOMED co-founder and  
Senior Public Health expert



#### Bianca Cucoș


Genomics expert



#### Adriana Boată

Health Communication  
expert

## SLOVAKIA



Narodny Onkologicky Ustav, Dep. Narodny Onkologicky  
Institut (NOU)  
National Cancer Institute, Dep. National Oncology Institute (NOI)



NOU is a specialized hospital focusing on providing complex oncological healthcare in Slovakia. NOI serves as a clinical research, academic and educational platform, contributing to implementation of the National Oncology Program.

### CONTRIBUTION



NOU dep. NOI will contribute to establishing and promoting the National Cancer Mission Hubs and their transnational networking and support the implementation of the Mission on Cancer at the national and regional levels in Slovakia.

### EXPECTATIONS



Joint cooperation on the creation of National Cancer Mission Hubs in member states and associated countries to implement the Cancer Mission objectives by close networking of all relevant stakeholders, policymakers, and citizens.



**Sona Ciernikova**

Main contact person and  
coordinator of all activities



**Maria Reckova**

Deputy coordinator of all  
activities



**Pavel Stukovsky**


Project manager



**Kristina  
Bubelinyova**

Administrative personnel

## SLOVAKIA



### Nadácia Výskum Rakoviny (NVR) Slovak Cancer Research Foundation



Nadácia Výskum Rakoviny is a non-profit organization established with the aim of promoting transdisciplinary research collaborations to enhance the quality of life and enable repeated treatment options for cancer patients.

#### CONTRIBUTION



Information sharing with consortium members, stakeholder involvement and participation at national level, organization of public events at national level aiming to create awareness for NCMHs.

#### EXPECTATIONS



Place the patient at the center of events, improve awareness of the need for transdisciplinary research in the field of quality of life, improve access to modern treatment using clinical trials.



#### Erika Chudějová

Legal representative of NVR,  
organization of public events  
at national level



#### Ján Sedlák

NVR board member,  
information sharing with  
consortium members,  
stakeholder involvement

## SPAIN



### Fundación TECNALIA Research & Innovation Foundation TECNALIA Research & Innovation



**tecna:la**

MEMBER OF BASQUE RESEARCH  
& TECHNOLOGY ALLIANCE

TECNALIA is the largest center of applied research and technological development in Spain, a benchmark in Europe and a member of the Basque Research and Technology Alliance. We collaborate with companies and institutions to improve their competitiveness, people's quality of life and achieve sustainable growth. We do it thanks to people who are passionate about technology and committed to building a better society.

- Our Mission: To transform technological research into prosperity.
- Our Vision: To be agents of transformation of companies and society for their adaptation to the challenges of a changing future.

We work with an increasingly strategic business relationship model based on trust, collaboration, and a shared technological approach. Some of our data; 115 m€ income, 1472 people in staff, 752 active patents, 20 active start ups. In the Health division we work closely with academic and clinical partners. we transfer our knowledge to biomedical sector industry. Our cancer research covers basic and applied research focused in the development of platforms for precision diagnosis and treatments.

We are the first private Spanish organisation in contracting, participation, and leadership in the European Commission's Horizon 2020 programme and we are ranked third in European patent applications.

### CONTRIBUTION



TECNALIA will participate in the Knowledge Exchange Program providing the expertise from the Spanish National Mirror Group on Cancer. This activity will enable the sharing of good practices and experience from the Spanish cancer hub in the process of designing the NCMH structure. We'll contribute to the active engagement of stakeholders, fostering cooperation.

### EXPECTATIONS



TECNALIA expects to become a reference stakeholder in the future EU network of National Cancer Mission HUBs. Our present expertise is focus in cancer research in diagnosis and treatment where we have a strong research network. This project will allow us to increase our present EU research network, but we are mainly interested in creating an EU network with stakeholders from cancer public health and cancer associations to work in strategic areas well aligned with the EU Cancer Mission.

## SPAIN



### Fundación TECNALIA Research & Innovation Foundation TECNALIA Research & Innovation



**tecnalia**

MEMBER OF BASQUE RESEARCH  
& TECHNOLOGY ALLIANCE



#### Olatz Murua

Coordinator. Main contact person for ECHOS project at Tecnalia. Head European & Cancer Mission Programs Health division



#### Carmen Pastor

Head of EU Programmes Health division



#### Ainhoa Egizabal

Project Manager Health division

## SWEDEN



### Karolinska Universitetssjukhuset, Region Stockholm (KUH, RS) Karolinska University Hospital, Stockholm Region



Karolinska  
Institutet

1793

KAROLINSKA  
UNIVERSITETSSJUKHUSET

Karolinska Comprehensive Cancer Center

Karolinska Comprehensive Cancer Centre brings together cutting-edge expertise in basic research, clinical research, and highly specialized cancer care. The centre is a joint initiative within Karolinska University Hospital and Karolinska Institutet. Karolinska Comprehensive Cancer Centre is the first Comprehensive Cancer Centre in Sweden to be accredited according to the Organization of European Cancer Institutes (OECI), a non-governmental, non-profit legal entity established in 1979 to promote greater collaboration between European cancer centre and institutes. The accreditation is a confirmation that the organizations meet the high-quality requirements that the OECI places on care, research, and education in the field of cancer. Karolinska University Hospital is one of Europe's leading university hospitals with a special responsibility for highly specialized care. Karolinska Institutet is one of Europe's highest-ranked medical universities. Together, we constitute a medical centre that conducts world-leading healthcare, research, and education. We have a significant role in the development of health care where new research findings and new treatment methods are continuously implemented to benefit the patients.

#### CONTRIBUTION



Karolinska CCC is dedicated towards systematically cooperate and partner with patients, to increase the involvement of patients in the development of care, research, and education in the field of cancer contributing for ECHoS with accumulated years of expertise in patient engagement and participation activities in cancer. Karolinska CCC brings a strong pool of knowledge and competences to enable the general and specific objectives for ECHoS in the creation and development of NCMHs capable of implementing Cancer Mission at national, regional, and local level. Through already established national and international networks, Karolinska CCC and Vision Zero Cancer with its pentahelix structure, have the ability and good conditions to lead a national hub for coordination and implementation of the Cancer Mission in Sweden and Europe.

#### EXPECTATIONS



A national Cancer Mission hub will be established in each Member State and a network will be formed between countries to support the implementation of the EU Cancer Mission. Activities will include awareness raising and coordination of the Cancer Mission between relevant actors in national, regional and local research and innovation and health systems, while creating and exploiting synergies with the EU Beating Cancer plan. This aims to promote an enhanced policy dialogue on cancer control at national, regional and local level.

SWEDEN



Karolinska Universitetssjukhuset, Region Stockholm (KUH, RS)  
Karolinska University Hospital, Stockholm Region



Karolinska Comprehensive Cancer Center

EXPECTATIONS (CONT.)



The national hub will complement the activities of the NCP.

Expected results are as follows:

- Cancer Mission is integrated into all cancer-related activities at national, regional and local level.
- Stakeholders in national, regional or local health and research and innovation systems are involved in the policy dialogue on cancer.
- Citizens, including patients, and national, regional and local stakeholders and decision-makers participate in the cancer policy dialogue.



**Eva Jolly**  
Task manager



**Patrik Rossi**  
Participant



**Dina Dabaghie**  
Participant



**Johanna Mayer**  
Participant



**Katarina  
Risbecker**  
Project financial/legal  
signatory



**Pablo Martí  
Andrés**  
Research Administrator



## SWEDEN



**Stiftelsen Stockholm School of Economics Institute for Research (SIR), coordinator of the Vinnova-funded innovation milieus VISION ZERO CANCER and TESTBED SWEDEN PRECISION HEALTH CANCER**  
Stockholm School of Economics Institute for Research  
Vision Zero Cancer



Vision Zero Cancer (Nollvision Cancer) and its flagship initiative Testbed Sweden for Clinical Trials and the Implementation of Precision Health in Cancer is a mission-oriented innovation ecosystem financed by Vinnova, Sweden's innovation agency and coordinated by SIR, Stockholm School of Economics Institute for Research. Launched in November 2019, Vision Zero Cancer's objective is to 'provide a national contact point for system innovation that contributes to reduce the incidence of cancer and to transform cancer from a life-threatening into a treatable or chronic disease in Sweden and globally'.

Core partners: Karolinska Comprehensive Cancer Centre, Swedish Association of Local Authorities and Regions, Stockholm School of Economics, AstraZeneca, Elekta, Roche.

The Stockholm School of Economics Institute for Research (SIR) is a Swedish national research institute with the overall aim to contribute to the advancement of the economic sciences through basic, as well as applied, research within a wider social science context. This research is carried out for the general benefit of the business community and society at large, and is to be conducted independent of political, religious, financial and other special interests.

### CONTRIBUTION



Vision Zero Cancer will contribute national and international networks, insights, methodology and hands-on experience in building, implementing and scaling a cancer mission-oriented innovation ecosystem. Vision Zero Cancer brings together stakeholders from the healthcare system, academia, industry, and civil society in the mission to beat cancer. The ambition is to deliver impact by putting research and innovation into a new role, combined with new forms of governance and collaboration.

Zero Cancer requires effective action across the full spectrum of prevention, early detection, treatment, survivorship and quality of life. We are therefore building a portfolio of different activities and projects with the ultimate goal to effectively cover the full spectrum; we currently develop methodology to ensure a systematic approach by combining opportunistic choices within the deliberate addressing of gaps and by formulating 'roads to impact'. We are working towards a future where healthcare is ever more human-centred, with patients being involved in research as an option within the healthcare ecosystem.



## SWEDEN



Stiftelsen Stockholm School of Economics Institute for Research (SIR), coordinator of the Vinnova-funded innovation milieus VISION ZERO CANCER and TESTBED SWEDEN PRECISION HEALTH CANCER  
Stockholm School of Economics Institute for Research  
Vision Zero Cancer



### EXPECTATIONS



A national Cancer Mission hub will be established in each Member State and a network will be formed between countries to support the implementation of the EU Cancer Mission.

Expected results are as follows:

- Cancer Mission is integrated into all cancer-related activities at national, regional and local level.
- Stakeholders in national, regional or local health and research and innovation systems are involved in the policy dialogue on cancer.
- Citizens, including patients, and national, regional and local stakeholders and decision-makers participate in the cancer policy dialogue.



**Ebba Hallersjö  
Hult**

Task manager



**Bettina Ryll**

Participant



**Johan  
Söderholm**

Project financial/legal  
signatory

## SWEDEN



# Regionala cancercentrum i samverkan (RCC) Confederation of regional cancer centres



The regional cancer centres (RCC) in Sweden support the nation's 21 county councils in increasing the quality of cancer care and improving outcomes, as well as maximising the efficiency of the use of health care resources throughout the patient pathways. RCC has a supportive, stimulating and coordinating role to develop cancer care according to the intentions of the national cancer strategy and Europe's Beating Cancer Plan. The mission is to meet the challenges and demands of tomorrow's cancer care through outreach and collaboration. RCC has developed systems and programmes to facilitate local, regional, and national collaboration.

## CONTRIBUTION

Regional Cancer Centres' (RCC) mission is to meet challenges and demands in tomorrow's cancer care through outreach and collaborative work. The RCC has developed structures for local, regional, and national collaborations both with patients and professionals and can serve as a model for other countries how to build an infrastructure for cancer care.

## EXPECTATIONS

Agree on a common definition of what a cancer mission hub is and how it relates to other network structures such as cancer comprehensive infrastructures. Establishment of a European network for cooperation and exchange of experience.



**Johan Ahlgren**

Associate professor, Head of  
Department, Regional  
Cancer Center MidSweden



**Helena  
Brändström**

Deputy national cancer  
coordinator

## TURKEY



# Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB) Health Institute Of Türkiye



TÜSEB (<https://www.tuseb.gov.tr/en>), the Health Institute of Türkiye, is a related entity of the Ministry of Health with a mission to lead R&D in the field of health science and technologies, and to support the practitioners and researchers scientifically, technically and financially, to increase domestication and nationalisation in a way that fulfil the needs of individuals in Turkey in line with developing technologies. As one of the institutes of TÜSEB, Türkiye Cancer Institute is the umbrella organization for the establishment of cancer mission hubs. Our main tasks are (i) to develop strategies to beat cancer and therefore supports national and international R&D activity, (ii) to fight against cancer by working in collaboration with national and international initiatives, academia, health sector and private sector in life sciences and medicine, (iii) to conduct and support research on the development of novel cancer therapeutics and efficient cancer detection methods, (iv) to create scientific support and establishment of coordination mechanisms for Clinical Research, (v) to lead creation and standardization of national cancer treatment guidelines. Türkiye Cancer Institute is the authorized institution to establish and coordinate the National Cancer Hubs to promote the implementation of EU Cancer Mission and European Beating Cancer Plan objectives in Türkiye.

## CONTRIBUTION

TUSEB, along with the other participants, will provide information about the diversity of national contexts and extract best practices for the development of the manual with general recommendations and guidelines for implementing National Cancer Mission Hubs (NCMHs) in each MS/AC. TUSEB may also participate in the validation of the draft manual and in the design of the final version of the NCMH.

Additionally, TUSEB is expected to develop a bespoke implementation plan for the creation or maturation of NCMHs in Turkey based on the produced guidelines and recommendations, and present it as a roadmap defining short-, medium-, and long-term goals and milestones for the implementation of NCMHs in their country/region.

## EXPECTATIONS

Implement and refine NCMHs according to their bespoke implementation plans.  
Assessing effectiveness of guidelines and identifying areas for improvement.  
Making sure the long-term sustainability of NCMHs

TURKEY



## Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB)

Health Institutes Of Türkiye



**Burak Civelek**  
Leading



**Gülhan Işık Ertop**  
Team member



**Ceren Sümer**  
Team member



**Ceren Sari**  
Team member



**Mertkaya Aras**  
Team member



**Tuba Özbay**  
Team member

## ECHoS ACKNOWLEDGES:





# ABBREVIATIONS

**AACC** | Alleanza Contro Il Cancro | Italy  
**AICIB** | Agência De Investigacao Clínica E Inovação Biomédica | Portugal  
**ASLIMICA** | Rigas Austrumu Kliniska Universitates Slimnica Sia | Latvia  
**CCRI** | Cyprus Cancer Research Institute | Cyprus  
**CSF** | Suomen Syöpäyhdistys -Cancerforeningen | Finland  
**Ry - Cancer Society Of Finland Csf** | Finland  
**CSO-MOH** | Ministry Of Health | Israel  
**DGS/MS** | Ministério Da Saúde - República Portuguesa | Portugal  
**DLR** | Deutsches Zentrum Fur Luft - Und Raumfahrt Ev | Germany  
**E.C.O.** | European Cancer Organisation | Belgium  
**EKT** | Ethniko Kentro Tekmiriosis Kai Ilektronikou Periechomenou | Greece  
**FNOL** | Fakultni Nemocnice Olomouc | Czech Republic  
**FNUSA-ICRC** | Fakultni Nemocnice U Sv. Anny V Brne | Czech Republic  
**GÖG** | Gesundheit Österreich Gmbh | Austria  
**HUS** | Hus-Yhtymä | Finland  
**IHBT** | Ustav Hematologie A Krevni Transfuze Praha | Czech Republic  
**IKNL** | Stichting Integraal Kankercentrum Nederland | Netherlands  
**INC** | Institut National Du Cancer | Luxembourg  
**INCa** | Institut National Du Cancer GIP | France  
**INOMED** | Asociatia Centrul Pentru Inovatie In Medicina | Romania  
**INT** | Fondazione Irccs Istituto Nazionale Dei Tumori | Italy  
**ISCIII** | Instituto De Salud Carlos III | Spain  
**KAUNO KLINIKOS** | Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno Klinikos | Lithuania  
**KCCC** | Karolinska Comprehensive Cancer Center | Sweden  
**KI** | Karolinska Institutet | Sweden  
**KU** | Klaipėdos Universitetas | Lithuania  
**KUH** | Karolinska University Hospital, Region Stockholm | Sweden  
**LIH** | Luxembourg Institute Of Health | Luxembourg  
**LMT** | Lietuvos Mokslo Taryba | Lithuania  
**LZP** | Latvijas Zinatnes Padome | Latvia

**NCBR** | Narodowe Centrum Badan I Rozwoju | Poland  
**NCCP-HSE** | Health Service Executive Hse | Ireland  
**NCI** | Nacionalinis Vėžio Institutas | Lithuania  
**NCS** | Kreftforeningen | Norway  
**NIJZ** | Nacionalni Institut Za Javno Zdravje | Slovenia  
**NIO-PIB** | Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie -Panstwowy Instytut Badawczy | Poland  
**NOU** | Narodny Onkologický Ústav | Slovakia  
**NUID UCD** | University College Dublin, National University Of Ireland, Dublin | Ireland  
**NVR** | Nadacia Vyskum Rakoviny | Slovakia  
**OCC** | Oslo Cancer Cluster SA | Norway  
**OOI** | Országos Onkológiai Intézet | Hungary  
**OUS** | Oslo Universitetssykehus HF | Norway  
**RCN** | Norges Forskningsråd | Norway  
**SALAR/RCC** | Sveriges Kommuner Och Regioner | Sweden  
**Sciensano** | Sciensano | Belgium  
**SINTEF** | Sintef AS | Norway  
**SIR** | Stiftelsen Stockholm School Of Economics (SSE) Institute For Research | Sweden  
**SMU** | Lietuvos Sveikatos Mokslu Universitetas | Lithuania  
**TECNALIA** | Fundacion Tecnalia Research & Innovation | Spain  
**TUH** | Sihtasutus Tartu Ülikooli Kliinikum | Estonia  
**TUSEB** | Türkiye Sağlık Enstitüleri Başkanlığı | Turkey  
**UCSC** | Università Cattolica Del Sacro Cuore | Italy  
**UHCSM** | Klinički Bolnički Centar Sestre Milosrdnice Ustanova | Croatia  
**UTARTU** | Tartu Ülikool | Estonia  
**VPC** | Augstākās Izglītības Un Zinātnes Informācijas Tehnoloģijas Koplietotāņu Pakalpojumu Centrs | Latvia  
**VU** | Vilniaus Universitetas | Lithuania  
**VULSK** | Viesoji Istaiga Vilniaus Universiteto Ligonine Santaros Klinikos | Lithuania



# ECHoS

Cancer Mission Hubs

CancerMissionHubs.eu

@ECHoS\_CMH



#ECHoS

#CancerMissionHubs



**FOLLOW  
US**



# ECHoS

Cancer Mission Hubs

[www.cancermissionhubs.eu](http://www.cancermissionhubs.eu)  
[coordination@cancermissionhubs.eu](mailto:coordination@cancermissionhubs.eu)



Join our  
**NEWSLETTER**



Funded by  
the European Union